AU732406B2 - Aryl thiophene derivatives as PDE IV inhibitors - Google Patents

Aryl thiophene derivatives as PDE IV inhibitors Download PDF

Info

Publication number
AU732406B2
AU732406B2 AU93347/98A AU9334798A AU732406B2 AU 732406 B2 AU732406 B2 AU 732406B2 AU 93347/98 A AU93347/98 A AU 93347/98A AU 9334798 A AU9334798 A AU 9334798A AU 732406 B2 AU732406 B2 AU 732406B2
Authority
AU
Australia
Prior art keywords
cycloalkyl
alkyl
pde
optionally substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU93347/98A
Other versions
AU9334798A (en
Inventor
Andre Giroux
Yongxin Han
Carole Lepine
Dwight Macdonald
Helene Perrier
Robert N. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808109.4A external-priority patent/GB9808109D0/en
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Assigned to MERCK FROSST CANADA & CO. reassignment MERCK FROSST CANADA & CO. Assignment by Applicant under S 113 Assignors: MERCK FROSST CANADA INC.
Publication of AU9334798A publication Critical patent/AU9334798A/en
Application granted granted Critical
Publication of AU732406B2 publication Critical patent/AU732406B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

WO 99/18099 PCT/CA98/00931 TITLE OF THE INVENTION ARYL THIOPHENE DERIVATIVES AS PDE IV INHIBITORS BACKGROUND OF THE INVENTION This invention relates to compounds and pharmaceutical compositions for the treatment of diseases by raising the level of cyclic (cAMP) through the inhibition of phosphodiesterase IV (PDE IV).
Many hormones and neurotransmitters modulate tissue function by elevating intra-cellular levels of 5'-cyclic adenosine monophosphate (cAMP). The cellular levels of cAMP are regulated by mechanisms which control synthesis and breakdown. The synthesis of cAMP is controlled by adenyl cyclase which may be directly activated by agents such as forskolin or indirectly activated by the binding of specific agonists to cell surface receptors which are coupled to adenyl cyclase.
The breakdown of cAMP is controlled by a family of phosphodiesterase (PDE) isoenzymes, which also control the breakdown of guanosine cyclic monophosphate (cGMP). To date, seven members of the family have been described (PDE I-VII) the distribution of which varies from tissue to tissue. This suggests that specific inhibitors of PDE isoenzymes could achieve differential elevation of cAMP in different tissues, [for reviews of PDE distribution, structure, function and regulation, see Beavo Reifsnyder (1990) TIPS, 11: 150-155 and Nicholson et al (1991) TIPS, 12: 19-27].
The availability of PDE isotype selective inhibitors has enabled the role of PDEs in a variety of cell types to be investigated. In particular it has been established that PDE IV controls the breakdown of cAMP in many inflammatory cells, for example, basophils (Peachell P.T. et al., (1992) J. Immunol. 148 2503-2510) and eosinophils (Dent G. et al., (1991) Br. J. Pharmacol. 103 1339-1346) and that inhibition of this isotype is associated with the inhibition of cell activation. Furthermore, elevation of cAMP in airway smooth muscle has a spasmolytic effect.
Consequently PDE IV inhibitors are currently being developed as potential anti-inflammatory drugs particularly for the prophylaxis and -1- WO 99/18099 PCT/CA98/00931 treatment of asthma, by achieving both anti-inflammatory and bronchodilator effects.
The application of molecular cloning to the study of PDEs has revealed that for each isotype there may be one or more isoforms.
For PDE IV, it is has been shown that there are four isoforms B, C and D) each coded for by a separate gene in both rodents (Swinnen J.V.
et al., (1989) Proc. Natl. Acad. Sci. USA 86 5325-5329) and man (Bolger G.
et al., (1993) Mol. Cell Biol. 13 6558-6571).
The existence of multiple PDE IVs raises the prospect of obtaining inhibitors that are selective for individual isoforms, thus increasing the specificity of action of such inhibitors. This assumes that the different PDE IV isoforms are functionally distinct. Indirect evidence in support of this comes from the selective distribution of these isoforms in different tissues (Swinnen et al., 1989; Bolger et al., 1993; Obernolte R. et al., (1993) Gene 129 239-247, ibid) and the high degree of sequence conservation amongst isoforms of different species.
To date full length cDNAs for human PDE IVA, B and D (Bolger et al., 1993 ibid; Obernolte et al., 1993 ibid; Mclaughlin M. et al., (1993) J. Biol. Chem. 268 6470-6476) and rat PDE IVA, B and D (Davis R.
et al., (1989) Proc. Natl. Acad. Sci. USA 86 3604-3608; Swinnen J.V. et al., (1991) J. Biol. Chem. 266 18370-18377), have been reported, enabling functional recombinant enzymes to be produced by expression of the cDNAs in an appropriate host cell. These cDNAs have been isolated by conventional hybridisation methods. However using this approach, only partial cDNAs for both human and rat PDE IVC have been obtained.
(Bolger et al., ibid. 1993 and Swinnen et al., ibid. 1989 and International Patent Specification No. WO 91/16457.) The design of PDE IV inhibitors for the treatment of inflammatory diseases such as asthma, has met with limited success to date. Many of the PDE IV inhibitors which have been synthesised have lacked potency and/or inhibit more than one type of PDE isoenzyme in a non-selective manner. PDE IV inhibitors that are relatively potent and selective for PDE IV, are reported to be emetic as well. Indeed this side effect has been so universal that experts have expressed their belief that WO 99/18099 PCT/CA98/00931 the emesis experienced upon administration of a PDE IV inhibitor, may be mechanism based.
We have now found a novel series of aryl thiophene derivatives, members of which compared to known structurally similar compounds are potent inhibitors of PDE IV at concentrations at which they have little or no inhibitory action on other PDE isoenzymes.. These compounds inhibit the human recombinant PDE IV enzyme and also elevate cAMP in isolated leukocytes. Certain compounds prevent inflammation in the lungs induced by carrageenan, platelet-activating factor (PAF), interleukin-5 (IL-5) or antigen challenge. These compounds also suppress the hyper-responsiveness of airway smooth muscle seen in inflamed lungs. Advantageously, compounds according to the invention have good oral activity and at orally effective doses exhibit little or none of the side-effects associated with known PDE IV inhibitors, such as rolipram. The compounds of the invention are therefore of use in medicine, especially in the prophylaxis and treatment of asthma and other inflammatory conditions.
SUMMARY OF THE INVENTION The invention encompasses novel compounds of Formula I useful in the treatment of disease by inhibition of PDE IV, resulting in an elevation of cAMP.
R
1
R
2 I Ar 1
R
3
S
I
The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.
-3- WO 99/18099 PCT/CA98/00931 DETAILED DESCRIPTION OF THE INVENTION The invention encompasses the novel compound of Formula I useful in the treatment of disease by inhibition of PDE IV, resulting in an elevation of cAMP, R1 R2 Ar R
S
I
or a pharmaceutically acceptable salt thereof wherein: Arl is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) C1-6alkyl, optionally substituted with -OH, -CO2H, C02C1- 3alkyl, and CN, b) C1-3alkoxy, c) C1-3alkylthio, d) C1-3alkylsulfinyl, e) C1-3alkylsulfonyl, f) C1-3fluoroalkyl, optionally substituted with -OH, g) halo, h) -OH, i) -CO2H, j) -CO2C1-3alkyl, k) 1) -CONR 4
R
5 m) -S(0)2NR 6
R
7 n) tetrazol-5-yl, or -4- WO 99/18099 WO 9918099PCT/CA98/00931 o) -CH=N-O-CH2002H; RI is selected from: a) hydrogen, b) C1-3alkyl, optionally substituted with -OH, or c) -XI- 1 -Ar 2 wherein: X1 is 1) -CH2-, or 2) a bond;
Y
1 is 1) -0- 3) -NR8-, or 4) a bond; Ar 2 is an aromatic ring selected from phenyl, naphthyl, pyrimidinyl, pyridinyl or thienyl, optionally substituted with up to two substituents chosen independently among: 1) C1-6ailkyl, 2) C1-6alkOxy, 3) -OH, 4) halo, or 5) CF3;
R
2 is selected from: a) hydrogen or b) C1..3alkYl.
R
3 is selected from phenyl, naphthyl, pyridinyl, furyl, thienyl, or ethinyl, optionally substituted with up to two substituents chosen independently among: a) C1-3alkyl, b) Cl-3fluoroalkyl, c) C1-6alkoxy, d) 01-3 fluoroalkoxy, f) halo, g) -OH, WO 99/18099 WO 9918099PCT/CA98/00931 h) -N021 i) -CH2 OH, j) -NHCONR 9 Rl 0 k) -S(O)2NR 11
R
1 2 1) -SCH2(1,1-c-Pr)GH2CO2H, mn) 1-piperazinyl, optionally substituted with C1..3alkyl, n) 4-inorpholinyl, or 0 -X 2 -y 2 -Ar 3 wherein,
X
2 is 1) -CH2-, 2) or 3) a bond; y 2 is 1) 2) or 3) abond; Ar 3 is phenyl, pyridinyl, pyrimidinyl or pyrazinyl, optionally substituted with up to two substituents chosen independently among: 1) C1-3alkyl, optionally substituted with -OH, or 2) -CH2CO2H.
R
4 and R 5 are independently selected from: a) hydrogen, b) C1-3alkyl, c) -S(O)201-3alkyl, or d) -S(O)2phenyl, optionally mono-substituted with C1..3alkyl, C1-3alkoxy, C1-3alkylthio or halo.
R
6 and R 7 are independently chosen from among: a) hydrogen, b) C 1 4 alkyl, c) -CO-Cl 1 4 alkyl, or d) -CO-phenyl, optionally Mono-substituted with C 1 3 alkyl, C1-3alkoxy, C1-3alkylthio or halo; WO 99/18099 PCT/CA98/00931
R
8 is chosen from among: a) hydrogen, or b)
R
9 and R 1 0 are independently chosen from among: a)hydrogen, b) C1-4alkyl, or c) phenyl; and
R
1 1 and R 1 2 are independently chosen from among: a) hydrogen or b) Within this embodiment there is a preferred genus of compounds wherein
R
1 is selected from a) C1-3alkyl, optionally substituted with -OH, or b) -X 1 -Yl-Ar 2
R
2 is hydrogen; and the remaining substituents are defined as in Formula I above.
Another preferred genus is that in which -X 1
-Y
1 is -CH2-Sand the remaining substituents are defined as in Formula I above.
Another preferred genus is that in which Ar 2 is pyrimidinyl, optionally substituted with up to two substituents chosen independently among: 1) C1-6alkyl, 2) C1-6alkoxy, 3) -OH, or 4) halo.
Still another preferred genus is realized when: -7- WO 99/18099 WO 9918099PCT/CA98/00931 Ar 1 is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) C1-6alkyl, optionally substituted with -OH, -CO2H, C02C1- 3alkyl, and CN, b) C1-3alkoxy, C) Cl-3alkylthio, d) 0 1-3alkylsulfinyl, e) C i-3alkylsulfony1, f) Cl-3fluoroalkyl, optionally substituted with -OH, g) halo, h) -OH, i) -CO2H, j) -002C1-3alkyl, R1 is selected from: b) C1-3alkyl, optionally substituted with -OH, or c) -Xl-yl-Ar 2 wherein:
X
1 is 1) -CH2-, or 2) a bond; Y' is 1) -0- 2) 3) or 4) a bond; Ar 2 is pyrimidinyl optionally substituted with up to two substituents chosen independently among: 1) C1-6alkyl, 2) C1-6alkOXY, 3) -OH, or 4) halo,
R
2 is selected from: a) hydrogen or -8- WO 99/18099 WO 99/ 8099PCT/CA98/00931
R
3 is selected from phenyl, naplithyl, pyridinyl, furyl, or thienyl, optionally substituted with up to two substituents chosen independently among: a) C1-.3alkyl, b) Cl-3fluoroalkyl, c) C1-6 alkoxy, d) 01-3 fluoroalkoxy, f) halo, g) -OH, h) -N02, i) -CH2 OH, j) -NHCONR 9
R
10 k) -S(O)2NRllRl 2 1) -SCH2(1,1-c-Pr)CH2CO2H or m) -X 2 -y 2 -Ar 3 wherein,
X
2 is 1) -0H2-, 2) or 3) a bond; y 2 is 1) 2) or 3) a bond; Ar 3 is phenyl, pyridinyl, or pyrimidinyl optionally substituted with up to two substituents, chosen independently among: 1) 01-3alkyl, optionally substituted with -OH, or 2) -CH2CO2H.
R
4 and R 5 are independently selected from: a) hydrogen, b) Cl-3alkyl, C) -S(O)2Cl-3alkyl, or
R
6 and R 7 are independently chosen from among: a) hydrogen, WO 99/18099 WO 991099PCT/CA98/00931 b) C 1 4 alkyl, C) -CO-C 1 4 alkyl, or
R
8 is chosen from among: a) hydrogen, or b)
R
9 and R 10 are independently chosen from among: a)hydrogen, b) C1-4alkyl, and
R
11 and R 12 are independently chosen from among: a) hydrogen or Yet another preferred genus is realized when: Ar 1 is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) C1-6alkyl, optionally substituted with -OH, -C02H, 002C1- 3alkyl, and ON, b) C1-3alkoxy, c) Cl-3alkylthio, d) C 1-3alkylsulfinyl, e) Cl-3alkylsulfonyl, f) Cl-3fluoroalkyl, optionally substituted with -OH, g) halo, h) -OHI i) -CQ2H, j) -CO2C1-3alkYlP RI is selected from: b) Cialkyl, optionally substituted with -OH, or c) -Xl-Y 1 -Ar 2 wherein: X1-Y 1 is CH 2
S;
WO 99/18099 PCT/CA98/00931 Ar 2 is pyrimidinyl optionally substituted with up to two substituents chosen independently among: 1) C1-6alkyl, 2) C1-6alkoxy, 3) -OH, or 4) halo,
R
2 is hydrogen;
R
3 is selected from phenyl, pyridinyl, furyl, or thienyl, optionally substituted with up to two substituents chosen independently among: a) C1-3alkyl, b) C1-3fluoroalkyl, c) C1-6alkoxy, d) Ci-3fluoroalkoxy, e) C1-3alkylthio, f) halo, g) -OH, h) -NO2, i) j) -NHCONR 9
R
1 0 k) -X 2
-Y
2 -Ar 3 wherein,
X
2 is 1) -CH2-, or 2) a bond; y2 is 2) or 3) a bond; Ar 3 is phenyl, pyridinyl, or pyrimidinyl optionally substituted with up to two substituents chosen independently among: 1) C1-3alkyl, optionally substituted with -OH, or 2) -CH2CO2H.
R
4 and R 5 are independently selected from: -11a) hydrogen; b) C1- 3 alkyl;
R
6 and R 7 are independently chosen from among: a) hydrogen; b) C1-4 alkyl;
R
8
R
1 1 and R 1 2 are chosen from among: a) hydrogen; or b) Ci-5 alkyl; and
R
9 and R 1 0 are independently chosen from among: a) hydrogen; b) C1-4 alkyl.
The disclosure also includes the following: A compound of Formula 1 as described above or composition thereof when used for treating: asthma or a phosphodiesterase (PDE) IV mediated disease by is increasing the cellular level of cAMP or by inhibiting phosphodiesterase (PDE) IV.
Use of a compound of Formula 1 as described above or composition thereof in the manufacture of a medicament for treating: asthma or a phosphodiesterase (PDE) IV mediated disease by increasing the cellular level of cAMP or by inhibiting phosphodiesterase (PDE) IV.
20 As appreciated by those of skill in the art, halo is intended to include F, Cl, Br and I.
For purposes of the specification alkyl is defined to include straight and branched, and cycloalkyl identifies cyclic structures of the indicated number of carbon atoms. By way of example C 1 -6 alkyl includes methyl, ethyl, propyl, I-propyl, s- and tbutyl, pentyl, hexyl and 1,1-dimethylethyl; and C3- 6 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Similarly, alkoxy, alkylthio, alkylsulfinyl, and alkylsulfonyl and cycloalkyloxy, cycloalkylthio, cycloalkylsulfinyl and cycloalkylsulfonyl mean the corresponding groups of the indicated number of carbon atoms of a straight, branched, or cyclic configuration, respectively. Examples of alkoxy groups include methoxy, ethoxy, propoxy and isopropoxy; examples of cycloalkyloxy include cyclopropyloxy, cyclohexyloxy, and the like.
Examples of alkylthio groups include methylthio, propylthio and isopropylthio; A cycloheptylthio is an example of cycloalkylthio. By way of illustration, the propylthio group signifies -SCH 2
CH
2
CH
3 Fluoroalkyl means an alkyl group of the indicated number of carbon atoms, of straight or branched structure, and fluoroxycycloalkyl means an alkyl [R:\LIBAA08614.doc:ACR 12a of cyclic structure of the indicated number of carbon atoms, in which one or more hydrogen atoms have been replaced by fluorine atoms; fluoroalkoxy, fluoroalkylthio, fluoroalkylsulfinyl, fluoroalkylsulfonyl, fluorocycloalkyloxy, fluorocycloalkylthio, fluorocycloalkylsulfinyl and fluorocycloalkylsulfonyl have the analogous meanings.
s Some of the compounds described herein contain one or more asymmetric centres and may thus give rise to diastereomers and .e [R:\LIBAA]08614.doc:ACR WO 99/18099 PCT/CA98/00931 optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.
Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
In a second embodiment, the invention encompasses pharmaceutical compositions for treatment of disease by inhibition of PDE IV, as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above.
Within this embodiment the invention encompasses pharmaceutical compositions for treatment of disease by inhibition of PDE IV, resulting in an elevation of cAMP, as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above.
For purposes of this specification a compound is said to selectively inhibit PDE IV in preference to other PDE's if the ratio of the concentration for all other PDE inhibition to PDE IV inhibition is 100 or greater.
The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the c ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted -13- WO 99/18099 PCT/CA98/00931 amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N--dibenzylethylenediamine, diethylamine, 2diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins,- procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.
Compounds according to the invention are selective and potent inhibitors of PDE IV. The ability of the compounds to act in this way may be simply determined by the tests described in the Examples hereinafter.
The compounds according to the invention are thus of particular use in the prophylaxis and treatment of human diseases where an unwanted inflammatory response or muscular spasm (for example bladder or alimentary smooth muscle spasm) is present and where the elevation of cAMP levels may be expected to prevent or alleviate the inflammation and relax muscle.
Particular uses to which the compounds of the invention may be put include the prophylaxis and treatment of asthma, especially inflamed lung associated with asthma, cystic fibrosis, or in the treatment of inflammatory airway disease, chronic bronchitis, eosinophilic granuloma, psoriasis and other benign and malignant proliferative skin diseases, endotoxic shock, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, diabetes Alzheimer's disease, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis and artherosclerosis.
Compounds of the invention also suppress neurogenic inflammation through elevation of cAMP in sensory neurones. They -14- WO 99/18099 PCT/CA98/00931 are, therefore, analgesic, anti-tussive and anti-hyperalgesic in inflammatory diseases associated with irritation and pain.
Compounds according to the invention may also elevate cAMP in lymphocytes and thereby suppress unwanted lymphocyte activation in immune-based diseases such as rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, transplant rejection and graft versus host disease.
Compounds of the invention suppress cytokine synthesis by inflammatory cells in response to immune or infectious stimulation.
They are, therefore, useful in the treatment of bacterial, fungal or viral induced sepsis and septic shock in which cytokines such as tumour necrosis factor (TNF) are key mediators. Also compounds of the invention suppress inflammation and pyrexia due to cytokines and are, therefore, useful in the treatment of inflammation and cytokinemediated chronic tissue degeneration which occurs in diseases such as rheumatoid or osteo-arthritis.
Over-production of cytokines such as TNF in bacterial, fungal or viral infections or in diseases such as cancer, leads to cachexia and muscle wasting. Compounds of the invention ameliorate these symptoms with a consequent enhancement of quality of life.
Compounds of the invention also elevate cAMP in certain areas of the brain and thereby counteract depression and memory impairment.
Compounds of the invention suppress cell proliferation in certain tumour cells and can be used, therefore, to prevent tumour growth and invasion of normal tissues.
For the prophylaxis or treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of Formula I together with one or more pharmaceutically acceptable carriers, excipients or diluents.
For the treatment of any of these, compounds of Formula I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non- WO 99/18099 PCT/CA98/00931 toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is -16- WO 99/18099 PCT/CA98/00931 mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethyl-cellulose, methylcellulose, hydroxypropylmethycellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or npropyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already -17- WO 99/18099 PCT/CA98/00931 mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Compounds of Formula I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable nonirritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
-18- WO 99/18099 PCT/CA98/00931 For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed.
(For purposes of this application, topical application shall include mouth washes and gargles.) Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the aboveindicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
Exemplifying the invention are: -19wo 99/18099 WO 99/ 8099PCT/CA98/00931 Example 1 Proton NMR (acetone-d6): 7.66 4H), 7.55 4H), 7.41 2H), 6.90 (s, 2H), 4.46 4H), 4.39 2H), 2.35 12H),1.56 12H1).
Example 2
OH
3
H
3
C
'Proton NMR (acetone-d6): 8.42 111), 7.75 (dd, 1H), 7.64 21H), 7.54 2H1), 7.41 1H1), 6.88 1H1), 6.80 1H1), 4.46 2H), 2.24 3H1), 1.55 3H).
wo 99/18099 WO 9918099PCT/CA98/00931 Example 3
OH
3 'Proton NMR (acetone-d6): 8.47(dd, 2H), 7.67-7.64 (in, 4H), 7.59-7.52 (in, 7.45 1H), 7.10 (dd, 1H), 6.95 (dd, 2H), 6.87 1H), 4.47 2H), 4.14 1H), 2.30 6H), 1.55 6H).
Example 4
H
3
CH
3 'Proton NMR (acetone-d6): 8.47(dd, 2H), 7.67-7.64 (mn, 4H), 7.59-7.52 (in, 7.45 1H), 7.10 (dd, 1H), 6.95 (dd, 2H), 6.87 1H), 4.47 2H), 4.14 1H), 2.30 6H), 1.55 6H).
-21wo 99/18099 WO 9918099PCT/CA98/00931 Example 0 0
F
'Proton NIMR (CDCl3): 9.85 (bs, 2H), 7.50-7.47 (mn, 4H), 7.31 1H), 7.28 1H), 6.90 2H), 6.69 1H), 4.42 2H), 3.45 (bs, 4H), 3.34 (bs, 4H), 2.50 3H), 2.37 6H).
Example 6 'Proton NMR (acetone-d6): 7.66 2H), 7.56-7.50 (mn, 5H), 7.24 2H), 7.07 2H), 6.97 2H), 6.89 1H), 5.12 2H), 4.44 2H), 3.85 (s, 3H), 3.53 2H), 2.34 6H).
-22wo 99/18099 WO 9918099PCT/CA98/00931 Example 7
CH
3
H
3 C_
~N
N==K
S
I N C 3
UCH
3 'Proton NMR (acetone-d6): 8.72 1H), 7.84 (dd, 1H), 7.59 1H), 7.55 2H1), 7.37 2H), 7.24 1H1), 6.87 1H1), 4.45 2H), 2.52 3H1), 2.48 3H), 2.32 6H).
Example 8
CH
3
H
3 C 100 238.800 (decomposed) Example 9
CH
3
H
3 CC h 0 -23- WO 99/18099 WO 99/ 8099PCT/CA98/00931 'Proton NMR (acetone-d6): 8.48 1H), 8.12 1H), 7.90 (dd, 1H), 7.89 1H), 7.66 2H), 7.55 2H), 7.54 1H), 6.88 1H), 4.47 2H), 4.18 1H), 3.49 4H), 2.32 6H), 1.55 1H), 3.49 4H), 2.32 (s, 6H), 1.55 Example 9H 3
I-
H
3
CH
3 'Proton NMIR (acetone-d6): 8.48 1H), 8.33 1H), 8.41 1H), 7.65 (in, 3H), 7.57-7.47 (in, 5H), 7.15 (dd, 1H), 6.87 1H), 4.47 1H), 4.11 1H), 2.31 6H), 1.55 6H).
Example 11
CH
3
H
3
C--
Proton NMR (acetone-d6):7.58 1H), 7.47 1H), 7.37 (dd, iHO, 7.35 (s, 1H),7.22 2H), 7.18 (dd, 1H), 6.97 1H), 6.89 1H)4.46 2H), 4.09 (s, 1H1, OH), 3.88 3H), 3.83 3H), 2.61 3H1), 2.34 6M1, 1.623 6H).
-24wo 99/18099 WO 9918099PCT/CA98/00931 Example 12
N-OH
Proton NMR (acetone-d6):11.21 1H), 8.61 (dd, 1H), 8.68 (dd, 1H), 8.64 (dd, 1H1), 7.94 (in, 1H), 7.71-7.56 (mn, 6H), 7.49 2H), 7.46 (mn, 1H), 6.89 (s, lIH), 4.48 2H), 4.17 1H), 2.33 6H), 1.58 6H).
Example 13
CH
3
~N
H
3
C
71.5*C WO 99/18099 WO 9918099PCT/CA98/00931 Example 14
CH
3
H
3 C ~N
H
3
C,
H
3
C'
0
CH
3 Proton NMR (acetone-d6)7.47 1H), 7.20 1H), 7.15 (dd, 1H), 7.13 (d, 1H),6.98-6.96 (in, 2H), 6.90 1H), 4.54 2H), 3.88 3H),3.82 3H), 2.36 6H1), 1.62 6H).
Example
CH
3 'Proton NMR (acetone-d6): 8.88 (dd, 1H1), 8.50 (dd, 1H1), 8.02 (ddd, 1H1), 7.68 1H1), 7.58 2H), 7.41 (mn, 1H1), 7.40 Cd, 2H1), 6.90 1H1), 4.48 2H), 2.55 311), 2.34 6H1).
-26- WO 99/18099 WO 9918099PCT/CA98/00931 Example 16
OH
3
H
3 C/
~N
OH
3 3
OH
3
OH
3 N CH3 Proton NMR (acetone-d6):8.42 (dd, 1H), 7.75 (dd, 1H), 7.650 2H), 7.54 (d, 52H), 7.2 1H), 6.189 1H), 6.8 1H), 4.6 2H),.5 .9t (s4H), 2.3 1.5 Cs H23 s, 6H) Example 18
OH
3
CH
3
NS
s0C3 H I\ CH Prto NR actoe-6:.2 dd 1),7.5 dd I) 765(d 2),7.40d -27- WO 99/18099 WO 9918099PCT/CA98/00931 Proton NMR (CDCl3):7.61 (dd, 2H), 7.57 (dd, 2H), 7.35 1H), 7.16 (dd, 1H), 7.08 1H), 6.86 1H), 6.69 1H), 4.47 2H), 3.93 3H), 3.90 (s, 3H), 2.63-2.56 (in, 2H), 2.44-2.36 (mn, 2H), 2.38 6H), 2.08 1H), 2.07-2.04 (mn, 1H), 1.76-1.73 (in,.1H) Example 19
CH
3 0 s OH Proton NMR (acetone-d6):7.57 2H), 7.55 2H), 7.54 1H), 7.37 (d, 2H), 7.06 2H), 6.88 1H), 4.43 2H), 3.84 3H), 3.78 2H), 2.66 (s, 2H), 2.44 2H), 2.34 6H), 0.52 (dd, 2H), 0.45 (dd, 2H).
Example
CH
3 Proton NMR (acetone-d6):8.45 1H), 7.80 (dd, 1H), 7.65 (dd, 2H), 7.55 (dd, 2H), 7.44 1H), 6.90 1H), 6.84 (sq, 1H), 4.47 2H), 3.74 411), 3.53 4H), 2.34 6H1), 1.55 6H).
-28- WO 99/18099 PTC9/03 PCT/CA98/00931 Example 21 01CH 3 'Proton NMR (acetone-d6): 7.55 2H), 7.49 1H), 7.18 (dd, 1H), 6.98 1H), 6.89 1H), 3.83 3H), 2.53 3H), 2.34 6H).
1H), 7.39 2H), 7.22 (d, 4.45 2H), 3.88 3H), Example 22
H
3 C Proton Nlvff (acetone-d6):8.1O 2H), 7.74 2H), 7.54 2H), 7.45 (s, 1H1), 6.97 2H), 6.89 1H), 4.50 2H), 4.36 2H), 3.16 (did, 4H), 2.93 (dd, 4H1), 2.32 6H), 1.39 3H).
-29- WO 99/18099 WO 9918099PCT/CA98/00931 Example 23 0-I
CH
3
CH
3 Proton NMR (acetone-d6):8.87 (dd, 1H), 8.28 (dd, 1H), 8.05 (dd, 1H), 7.56 1H1), 7.25 Cd, 1H), 7.19 (dd, 1H), 6.98 1H), 6.87 1H), 4.48 2H), 3.38 3H), 3.83 3H), 2.81 3H), 2.29 3H).
Example 24
H
3
H
NH
Proton NMR (ODCl3):7.71 2H), 7.48-7.46 (in, 2H), 7.44 1H), 7.43 Ct, 1H), 7.30 2H), 7.12 1H), 6.74 Cs, 1H), 4.47 Cs, 1H), 3.33 4H), 2.50 (s, 3H), 2.43 Cs, 6H), 1.02 Ct, 6H).
WO 99/18099 WO 9918099PCT/CA98/00931 Example
H
3
C'\
"CH 3
H
3 C OH Proton NNM (CDCl3):7.63 2H), 7.58 2H), 7.34 1H), 7.16 (dd, 1H), 7.09 (dd, 1H), 6.85 1H), 6.69 1H), 4.45 2H), 4.31-4.21 (in, 2H), 3.93 3H), 3.90 3H), 3.81 1H), 2.37 6H), 1.80 3H), 1.28 3H).
Example 26 eCH 3
H
3 C .3N Proton NMR (acetone-d6):8.48 1H), 7.65 2H), 7.55 2H), 7.53 (s, 1H), 7.24 1H), 7.15-7.11 (mn, 2H), 6.90 1H),6.80 (dd, 1H), 4.47 2H), 4.04 1H), 2.34 6H) 1.55 6H).
-31- WO 99/18099 WO 9918099PCT/CA98/00931 Example 27
/CH
3 187.7C0 (decomposed) Example 28 0 0 Proton nMR (acetone-d6):8.45 1H), 8.16 (ddd, 1H), 8.08 (ddd, 1H), 7.83 1H),7.72 1H), 7.59 2H)) 7.42 2H), 4.49 2H),2.55 3H), 2.35 6H).
-32- WO 99/18099 WO 99/ 8099PCT/CA98/00931 Example 29 cI Proton NMR (acetone-d6):8.69 (dd, 1H), 7.84 (dd, 1H), 7.66 2H), 7.58 (s, 1H), 7.56 2H), 7.31 1H), 4.48 2H1), 4.09 1H), 2.33 611), 2.13- 2.04 (mn, 1IH), 1.55 6H1), 1.10-0.97 (mn, 4H1).
Example
,,CH
3 Proton NMR (CDCl3):10.88 1H1), 8.05 (dd, 1H1), 7.69 (dd, 111), 7.32 (s, 111), 7.13 (dd, 111), 7.08 1H1), 7.02 111), 6.88 1H), 6.69 1H1), 4.40 2H), 3.93 3H), 3.90 3H), 2.37 6H), 1.38 3H).
-33wo 99/18099 WO 9918099PCT/CA98/00931 Example 31 Proton NMR (CDCl3): 8.83 1H), 8.49 (dd, 1H), 7.82 (dd, 1H), 7.51 (s, 1H), 7.28 (dd, 1H), 6.67 1H), 4.47 2H), 2.38 6H),1.62 6H).
Example 32
H
3
C-
Proton NMR (CDCl3):8.29 (in, 1H), 8.18 2H), 7.89-7.84 (mn, 2H), 7.76 2H), 7.58 1H), 7.52-7.46 (in, 3H), 7.40 1H),6.70 1H), 4.55 (s, 2H), 2.36 6H).
-34 wo 99/18099 WO 9918099PCT/CA98/00931 Example 33 0 -CH 3 Proton NMR (CDCl3):7.64 2H), 7.54 2H), 7.30 1H), 7.10 (dd, 1H), 7.05 111), 6.85 1H), 6.67 1H), 4.43 2H), 3.90 3H), 3.88 3H), 3.69 1H1), 2.35 6H1), 1.84 3M1.
Example 34
CH
3
H
3
C
Proton NNM (acetone-d6):8.15 211), 7.78 211), 7.68 211), 7.63 Cs, 1H),7.42 2H), 7.32 111), 6.88 1H), 4.53 2H1),2.32 611).
wo 99/18099 WO 9918099PCT/CA98/00931 Example Proton NM (acetone-d6):11.30 (bs, 1H), 8.14 2H), 7.76 2H), 7.51 (s, 1H),7.23-7.18 (mn, 2H), 6.99 1H), 6.90 1H), 4.90 (mn, 1H), 4.50 2H), 3.82 3H), 2.32 6H), 1.95-1.60 (in, 8H).
Example 36 Proton NMR (ODCl3):8.80 (dd, 1H1), 8.48 (dd, 1H), 7.83 (dd, 1H), 7.60 (dd, 2H), 7.57 (dd, 2H), 7.50 1H), 7.29 (dd, 1H), 6.71 1H), 4.47 2H), 2.64- 2.57 (mn, 2H), 2.45-2.40 (mn, 3H), 2.39 6H), 2.07-2.04 (mn, 1H), 1.75-1.70 (mn, 1H) -36wo 99/18099 WO 9918099PCT/CA98/00931 Example 37 Proton NMR (acetone-d6):10.81 1H), 8.48 (dd, IFH), 7.93 (dd, 1H), 7.80 (in, 1H1), 7.71 2H), 7.65 2H1), 7.63 1H), 7.57 2H1), 7.48 2H), 7.33 (mn, 1H1), 6.88 1H1), 4.50 211), 4.15 1H1), 2.33 611), 1.57 (s, 611).
Example 38 152.70C -37 wo 99/18099 WO 9918099PCT/CA98/00931 Example 39 Proton NMR (CDCl3):8.15 2H), 7.70 2H), 7.52 1H), 7.47-7.45 (in, 2H),7.25 (mn, 1H), 6.70 1H), 4.48 2H), 2.37 6H).
Example
CH
3 H C/ ~N Proton NMIR:7.74 1H), 7.46 1H), 7.40 (dd, 1H), 7.23 1H), 7.18 (dd, 1H), 7.08 1H), 6.98 1H), 6.95 1H)6.91 1H), 6.40 (d, 1H), 4.43 2H), 3.90 3H) 3.88 3H), 3.83 3H1), 2.35 6H), 1.28 (s, 6H).
-38wo 99/18099 WO 9918099PCT/CA98/00931 Example 41 Proton NMR (acetone-d6) 7.56 2H), 7.50 2H), 2H), 7.48 1H), 7.23 1H), 7.18 (dd, 1H), 6.98 1H), 6.90 1H), 4.91 (in, 1H),4.45 2H), 4.25 OH), 3.88 3H), 3.83 3H) 2.34 6H), 1.44 3H).
Example 42 Proton NMIR (CDCl3): 8.15 (di 2H), 7.69 2H), 7.60 (in, 1H1), 7.43 (mn, 1H), 7.40 1H), 7.14 1H1), 6.71 IH), 4.46 2H), 2.37 611).
-39 wo 99/18099 WO 9918099PCT/CA98/00931 Example 43 Proton NMR: (acetone-d6) 7.83 (dd, 1H), 7.49 1H), 7.48 (in, 1H), 7.26-7.18 (mn, 3H), 6.99 6.91 1H), 6.82 1H), 6.56 1H), 4.43 (s, 2H), 3.88 Cs, 3H) 3.83 3H), 2.34 6H), 1.26 6H).
Example 44 URMS: 568.1398 (caic.: 568.1400).
wo 99/18099 WO 9918099PCT/CA98/00931 44 Example Proton NMR (acetone-d6): 7.60 2H), 7.56 2H), 7.53 1H), 7.39 (d, 2H), 7.04 2H), 6.89 1H), 4.64 2H), 4.44 2H), 4.21 1H), 3.85 (s, 3H), 2.35 6H).
Example 46
CH
3 0
-CH
3 Proton NMR (acetone-d6fDMSO-d6): 7.92 1H), 7.52 1H), 7.25-7.16 (mn, 4H), 7.00 1H), 6.91 1H), 4.52 2H), 3.88 3H), 3.83 3H), 2.36 6H).
-41wo 99/18099 WO 99/ 8099PCT/CA98/0093 1 Example 47 Proton NMR (acetone-d6): 7.80 4H), 7.51 1H), 7.24 1H), 7.20 (dd, 1H), 6.98 1H), 6.88 1H), 4.48 2H), 3.88 3H), 3.84 3H), 2.75 (s, 3H), 2.32 6H).
Example 48 0
CH
3 Proton NNM (acetone-d6): 7.52 2H), 7.47 1H), 7.37 1H), 7.23 (d, 1H), 7.17 (dd, 1H), 6.97 1H), 6.89 1H), 4.46 2H), 3.88 3H), 3.82 3H), 3.40 1H, OH), 2.79 2H), 2.34 6H), 1.18 6H).
-42- WO 99/18099 WO 9918099PCT/CA98/00931 i, Example 49 FIRMS: 439.0609 (caic.: 439.0610).
Example Proton NMR (acetone-d6): 8.74 1HI), 7.88 (dd, 11H), 7.66 2H), 7.61 1HI), 7.56 2H), 7.27 1H), 6.89 1HI), 4.49 2H), 4.10 (bs, 1H, OH), 2.50 3H), 2.33 6H), 1.55 6H).
-43 wo 99/18099 WO 99/ 8099PCT/CA98/00931 4' Example 51 Proton NMR (acetone-d6): 7.66 2H), 7.60 2H), 7.58 1H), 7.50 (d, 2H), 7.48 2H), 7.30 1H), 6.89 1H), 4.70 2H), 4.47 2H), 4.31 (t, 1H) OH), 2.34 6H).
Example 52 HIRMS: 467.0655 (caic.: 467.0654).
-44wo 99/18099 WO 991099PCT/CA98/00931 Example 53 0
-CH
3 Proton NMR (acetone-d6): 7.54 2H), 7.44 1H), 7.21 1H), 7.15 (dd, 1H), 7.00 2H), 6.95 1H), 6.87 1H), 4.41 Cs, 2H), 3.87 3H), 3.84 (s, 3H), 3.82 Cs, 3H), 2.33 6H).
Example 54 Proton NMR (ODCl3): 8.85 1H), 8.50 1H), 8.15 Cd, 2H), 7.83 (dmn, 1H), 7.68 2H), 7.50 1H), 7.30 (dd, 1H), 6.65 1H1), 4.47 2H), 2.37 Cs, 6H1).
WO 99/18099 WO 99/ 8099PCT/CA98/00931 Example
CH
3
O-CH
3 Proton NMR (acetone-d6): 10.83 1H, OH), 7.93 1H), 7.52 1H), 7.25-7.19 (in, 4H), 6.99 1H), 6.90 1H), 4.52 2H), 3.99 3H), 3.89 3H), 3.84 3H), 2.34 6H).
Example 56
CH
3
H
3 C4
LO=
Proton NTM (acetone-d6): 7.68 2H), 7.60 2H), 7.54 2H), 7.47 (s, 1H), 4.50 2H), 3.83 3H), 3.02 6H), 2.33 6H).
-46- WO 99/18099 WO 9918099PCT/CA98/00931 Example 57
,CH
3 Proton NNM (acetone-d6): 8.00 2H), 7.80 2H), 7.53 1H), 7.25 (d, 1H), 7.21 (dd, 1H), 7.00 1H), 6.90 1H), 6.64 (bs, 2H, NH2), 4.50 (s, 2H), 3.89 3H1), 3.84 3H1), 2.33 6H1).
Example 58
CH
3
H
3 C 100 Proton NMR (acetone-d6): 8.12 211), 7.97 (bs, 1H), 7.72 211), 7.63 (in, 1H), 7.40 111), 6.88 111), 6.79 (mn, 1H), 4.48 211), 2.30 611).
-47 WO 99/18099 WO 9918099PCT/CA98/00931 Example 59
CH
3
H
3 C HO ~,CH 3 H S" 0 FIRMS: 479.0921 (calc.: 479.0919).
Example
CH,
N
S
H,
F
H3CH, 0-(
F
'Proton NMR (acetone-d6): 7.67 Kd 2H), 7.62 2H), 7.60-7.51 3H), 7.39 (in, 1H), 7.09 1IH), 7.00 1H), 6.89 1H), 4.47 2H), 4.09 (s2 1H), 2.31 6H), 1.52 6H).
Example 61 CH3 s ,C' 'Proton NMR (acetone-d6): 7.90 2H), 7.80 2H), 7.61 1H), 7.52 (s, 1H), 7.20 (dd, 1H), 7.00 1H), 6.89 1H), 4.50 2H), 3.88 Cs, 3H), 3.83 3H1), 2.35 Cs, 611).
-48wo 99/18099 WO 9918099PT/CA98/00931 Example 62 'Proton NMR (acetone-d6): 7.66 2H), 7.53 2H), 7.49 1H), 7.24 (d, 1H), 7.19 (dd, 1H), 6.99 1H), 6.90 1H), 4.46 Cs, 2H), 4.04 2H), 3.88 3H), 2.34 6H).
Example 63
ZCH
3 'Proton NMR (acetone-d6): 7.58 2H), 7.48 1H), 7.45 211), 7.21 (d, 1H1), 7.18 (dd, 1H1), 6.98 1H1), 6.89 1H1), 4.46 2H), 3.88 311), 3.83 311), 3.70 211), 2.34 6H).
Example 64 -49wo 99/18099 WO 9918099PCT/CA98/00931 'Proton NMR (acetone-d6): 8.16 2H), 7.77 2H), 7.55-7.53 (mn, 2H), 7.50 1H), 7.43-7.41 (mn, 3H), 6.90 1H), 4.50 2H), 2.32 6H).
Example
HCH,
'CIMS: MH+: 517.2 Example 66
CH
3
H
3 C 0 1 CH 3 'Proton NMR (acetone-d6): 8.05 2H), 7.88 2H), 7.54 1H), 7.25 (d, 1H), 7.20 (dd, 1H),7 7.00 1H), 6.89 1H), 4.51 2H), 3.88 3H), 3.84 3H), 3.17 3H), 2.32 6H).
Example 67
CH
3 WO 99/18099 WO 9918099PCT/CA98/00931 Proton NMR (acetone-d6): 8.55 2H), 7.71 1H), 7.59 2H), 7.41 (d, 1H), 7.28 1H), 7.26 1H), 7.00 1H), 4.92 (in, 1H), 3.85 3H1), 1.95- 1.60 (nm, 811).
Example 68 X0 'Proton NMR (acetone-d6): 8.04 2H), 7.71 2H), 7.49 1H1), 7.22- 7.18 (in, 2H), 6.99 1H), 6.90 1H1), 4.92 (mn, 1H), 4.49 2H), 3.83 3H1), 2.33 6H1), 2.00-1.60 (mn, 811).
Example 69 'Proton NMR (0D013): 7.58 211), 7.40 211), 7.33 1H), 7.14 (dd, 1H), 7.08 111), 6.85 1H1), 6.67 111), 4.73 2H), 4 .42 2H), 3.90 3H), 3.87 3H1).
Example -51wo 99/18099 WO 991099PCT/CA98/00931 'Proton NMR (acetone-d6): 8.11 2H), 8.05 2H), 7.70 (in, 1H), 7.57- 7.42 (mn, 7H), 7.27 1H), 6.83 1H), 4.44 2H), 2.28 6H1).
Example 71 .CH3 'Proton NMR (acetone-d6): 11.18 1H), 8.11 1H), 7.78 (dd, 1H), 7.47 1H1), 7.23 1H1), 7.17 (dd, 1H), 7.08 1H1), 6.96 1H1), 6.87 (s, 1H1), 4.42 2H1), 3.88 3H1), 3.83 3H), 2.33 6H).
-52- WO 99/18099 WO 9918099PCT/CA98/0093 1 Example 72
H
3
C,
'Proton NMR (acetone-d6): 8.51 (in, 1H), 7.83-7.76 (mn, 3H), 7.25-7.16 (in, 3H), 7.07 1H), 6.91 1H), 4.48 2H), 3.86 3H), 3.83 3H), 2.36 6H).
Example 73 C113 H3C 0 61 ,CH 3 100 'Anal.: C 63.07, H 4.92, N 5.69, S 12.60; (caic.: C 63.4, H 4.92, N 5.69, S 12.99).
-53wo 99/18099 WO 9918099PCT/CA98/00931 Example 74
,CH
3 135.300 Example 'Proton NMR (CDCl3): 7.88 2H), 7.69 2H), 7.50 2H), 7.36 (s, 1H1), 6.90 2H), 6.70 1H), 4.46 2H), 3.85 3H), 2.36 6H).
Example 76 -54- WO 99/18099 WO 9918099PCT/CA98/00931 Proton NMR (CDCl3): 9.12 1H), 7.39 (dd, 1H), 7.32 1H), 7.31 1H), 7.13 (dd, 1H), 7.07 1H), 6.92 1H), 6.85 1H), 6.71 1H), 4.40 (s, 2H), 3.93 3H), 3.90 3H), 2.55 1H), 2.40 6H), 1.69 6H1).
Example 77
CH
3 H
N
3I 'Proton NMR (acetone 8.90 (dd, 1H), 8.52 (dd, 1H1), 8.05-8.01 (in, 3H), 7.83 2H1), 7.74 1H1), 7.43 (ddd, 1H), 6.90 1H1), 6.67 (bs, 2H1, N112), 4.53 211), 2.32 6H).
Example 78
ICH
3 146.1*C.
wo 99/18099 WO 9918099PCT/CA98/00931 Example 79 'Proton NMR (acetone-d6): 12.33 1H), 8.08 1H), 7.71 (dd, 1H), 7.44 1H), 7.20 1H), 7.13 (dd, 1H), 7.02 1H), 6.93 1H), 6.86 (s, 1H), 4.42 2H1), 3.87 3H), 3.81 3H), 2.63 3H), 2.32 6H1).
LO Example
CH
3
H
3 C N 'Proton NMR (acetone-d6): 7.45 1H), 7.19 1H1), 7.15 (dd, 1H), 6.97 1H1), 6.89 1H), 6.575 1H1), 6.36 1H1), 4.60 2H), 4.32 1H, OH), 3.88 3H1), 3.82 3H1), 2.37 6H), 1.57 6H).
-56- WO 99/18099 WO 9918099PCT/CA98/00931 Example 81 CH3
H
3 C
~N
NK-
ICH3 Proton NMR (acetone-d6): 7.51 1H), 7.48 1H), 7.45 (dt, 1H), 7.37 (t, 1H) 7.29 (dt, 1H), 7.22 1H), 7.17 (dd, 1H), 6.97 1H), 6.89 1H1), 4.45 2H1), 3.88 3H), 3.82 3H), 3.40 1H, OH), 2.80 2H1), 2.34 6H1), 1.16 LO Example 82 'Proton NMR (ODC13): 8.11 211), 7.56 2H), 7.18-7.06 (in, 4H), 6.91- 6.82 (in, 311), 6.75 (mn, 1H), 4.83 (in, 111), 4.14 2H), 3.86 311), 3.72 (s, 3H), 2.00-1.60 (mn, 8H).
-57 WO 99/18099 WO 9918099PCT/CA98/0093 I Example 83 'Proton NMIR (acetone-d6): 8.07 Cd, 2H), 7.55 (dd, 1H), 7.52 2H), 7.25 1H), 7.20 (mn, 2H), 7.08 (dd, 1H), 7.03-6.99 (in, 2H), 4.12 2H), 3.85 (s, 3H), 2.00-1.60 (mn, 8H).
Example 84
H
3 C
CH
3 'Proton NMR (DMSO-d6): 8.43 Cd, 1H1), 8.01 2H), 7.67 Cd, 2H), 7.58 (d, 2H), 7.49 1H), 7.09 Cd, 1H), 6.99 Cd, 2H), 4.46 Cs, 2H), 3.78 3H), 2.30 3H).
58 WO 99/18099 WO 9918099PCT/CA98/00931 Example ,-c0 ,CH3
:H
3 Proton NMR (acetone-d6): 8.76 1H), 8.68 1H), 8.09 1H), 7.52 (s, 1H) 7.24 1H), 7.20 (dd, 1H), 7.00 1H), 6.88 1H) 4.46 2H), 3.88 3H), 3.83 3H), 2.32 6H), 1.58 6H).
Example 86
F
'Proton NMR (acetone 8.10 2H), 7.67 2H), 7.43-7.30 (in, 3H), 7.21 1H), 7.20 (dd, 1H), 7.13 1H), 7.12 (dmn, IH), 7.00 1H), 4.27 2H), 3.89 3H), 3.84 3H).
Example 87 -59 WO 99/18099 WO 9918099PCT/CA98/0093 1 'Proton NMM (acetone 9.22 (bs, 1H, OH), 8.01 (dd, 111), 7.62 2H), 7.53 2h), 7.44 1H1), 7.23 1H), 7.17 (dd, 1H), 7.12 (dd, 1H), 7.00- 6.96 (in, 2H), 4.47 2H1), 4.13 111, OH), 3.88 3H), 3.83 311), 1.56 6H1).
Example 88
CH
3
H
3 C_
N
'Proton NMR (CDCI3): 8.62 (mn, 2H), 7.50 (in, 211), 7.34 1H), 7.14 (dd, 1H1), 7.07 1H), 6.86 1H), 6.69 1H1), 4.50 211), 3.93 3H), 3.88 311), 2.35 611).
Example 89
CH
3 H C/ ~N H3C OH 'Proton NMR (acetone-d6): 7.70 (dd, 111), 7.46 1H1), 7.45-7.30 (in, 311) 7.23 111), 7.17 (dd, 111), 6.97 111), 6.85 111) 6.66 211), 6.45 111), 4.18 211), 3.88 311), 3.83 3H), 2.31 611), 1.31 611).
WO 99/18099 WO 9918099PCT/CA98/00931 Example Proton NMR (acetone-d6): 7.71 1H), 7.62 Cm, 1H), 7.50 1H), 7.25- 7.17 (in, 3H), 6.98 1H), 6.87 Cs, 1H), 4.35 Cs, 2H), 3.88 Cs, 3H), 3.83 (s, 3H), 2.31 6H), 1.54 6H).
Example 91 0 0 'Proton NMR (acetone-d6): 8.28 (mn, 1H), 8.16 Cd, 2H), 8.00 2H), 7.85 Cd, 2H), 7.64 (in, 1H), 7.57-7.53 (in, 3H), 7.51 1IH), 6.90 Cs, 1H), 4.60 Cs, 2H), 3.42 3H), 2.32 Cs, 6H1).
-61 wo 99/18099 WO 9918099PCT/CA98/0093 I Example 92 ci 'Proton NMR (acetone-d6): 8.83 2H), 8.29 1H), 8.27 2H), 7.25- 7.20 (in, 2H), 7.11 1H), 6.93 1H), 4.55 2H), 3.88 3H), 3.84 (s, 3H), 2.35 6H1).
Example 93 0
-CH
3 'Proton NMR (CDCl3): 7.60 (dd, 2H), 7.44 2H1), 7.44-7.40 (in, 2H), 7.14 (dd, 1H1), 7.08 1H1), 6.86 Cd, 11H), 6.68 1H1), 4.46 21H), 3.93 3H), 3.90 3H), 2.37 6H).
-62- WO 99/18099 WO 9918099PCT/CA98/00931 Example 94 'Proton NMR (acetone 8.09 2H), 7.64 2H), 7.33 1H), 7.21- 7.18 (mn, 2H1), 7.11 (bs, IH), 7.06 1H), 7.00 1H), 6.95 (bd, 1H1), 4.19 211), 3.89 3H), 3.85 Cs, 3H).
Example Proton NMR (acetone 8.07 Cd, 2H), 7.87-7.73 (in, 4H), 7.65 2H), 7.51-7.42 (mn, 3H), 7.41 1H1), 7.18-7.16 (mn, 2H), 6.98 1H1), 4.40 (s, 2H1), 3.84 Cs, 3H), 3.83 3H).
-63 wo 99/18099 WO 99/ 8099PCT/CA98/00931 Example 96 .'CH3 'Proton NMR (CDG13): 8. 11 2H), 7.59 2H), 7.26-7.20 (mn, 2H), 7.17 1H), 7.10 (dd, 1H), 7.07 1H), 6.88-6.79 (mn, 3H),4.83 (mn, 1H), 4.12 2H), 3.86 3H), 3.80 3H), 2.00-1.60 (in, 8H).
Example 97
/CH
3 0
-CH
3 'Proton NMR (acetone 8.09 2H), 7.65 2H), 7.39 1H), 7.23- 7.17 3H), 7.00 1H), 6.91 (dma, 1H), 6.88 1H), 6.79 (ddd, 1H), 4.28 2H), 3.89 3H), 3.85 3H), 3.73 3H).
Example 98 Proton NMR (acetone-d6): 8.52 1H), 7.83 (in, 2H), 7.71 1H), 7.38 (d, 1H), 7.25 (mn, 3H), 7.00 1H), 4.95 (in, 1H), 3.82 3H), 1.95-1.60 (in, 8H).
-64wo 99/18099 WO 9918099PCT/CA98/0093 1 Example 99 'Proton NMR (acetone-d6): 8.81 (in, 1H), 8.59 (dd, 1H), 7.99 (din, 1H), 7.52 1H), 7.50 1H), 7.25 1H), 7.20 (dd, 1H), 7.00 1H), 6.89 (s, 1H), 4.47 2H), 3.88 3H), 3.85 3H), 2.33 6H).
Example 100 0
-CH
3 'Proton NMR (acetone 810 2H), 7.64 2H), 7.38 1H), 7.34- 7.28 (in, 4H), 7.23-7.19 (in, 2H), 7.00 1H), 4.29 2H), 3.90 (s, 3H), 3.85 3H).
WO 99/18099 WO 9918099PCT/CA98/00931 Example 101
CH
3 'Anal: C5.04,H 36 NC471 Exmpe 0
O.-CH
3 Proton NIM (acetone-d6): 8.10 2H), 7.64 2H), 7.37 1H), 7.23-7.18 (in, 2H), 7.00 1H), 6.92 2H), 6.85 1H), 4.23 2H), 3.89 3H), 3.84 3H), 2.18 6H).
Example 103 -66wo 99/18099 WO 9918099PCT/CA98/00931 'Proton NMR (acetone-d6): 8.08 2H), 7.60 2H), 7.35 1H1), 7.22 (d, 1H1), 7.20 (dd, 1H1), 7.09 (bs, 1H1), 7.06-6.99 (in, 311), 4.19 211), 3.89 (s, 3H1), 3.85 3H), 2.20 3H1), 2.15 311).
Example 104
CH
3 _0
OCH
3 0
-CH
3 'Proton NMR (acetone-d6): 8. 11 211), 7.70 211), 7.36 1H1), 7.29- 7.18 (in, 411), 7.00 111), 6.95 (dd, 111), 6.87 (td, 111), 4.20 211), 3.90 311), 3.84 3H), 3.80 311).
Example 105
CH
3
H
3
C
Example 106 -67- WO 99/18099 WO 99/ 8099PCT/CA98/00931 113.9*0 Example 107 0 -CH 3 Proton NMR (acetone-d6): 7.56 (dd, 2H), 7.51 1H), 7.25 1H), 7.19 (dd, 1H), 7.05 (dd, 2H), 6.98 1H)2 6.83(s, 1H), 5.32 2H), 3.89 3H), 3.85 3H), 3.83 3H), 2.35 6H).
Example 108 0
-CH
3 Proton NMR (acetone-d6): 8.57 2H), 8.14 2H), 7.75 2H), 7.52 (s, 1H), 7.26 1H), 7.21 (dd, 1H)) 7.17 1H), 7.00 1H), 4.52 211), 3.89 311), 3.84 3H).
Example 109
/CH
3
CH
3 -68wo 99/18099 WO 99/ 8099PCT/CA98/00931 'Proton NMR (acetone-d6): 7.64 (dd, 2H), 7.58 (dd, 2H), 7.55 1H1), 7.27 1H1), 7.20 (dd, 1H1), 6.99 1H), 6.83 1H), 5.36 2H), 3.90 (s, 3H), 3.84 3H), 2.35 6H), 1.55 6H).
Example 110 'Proton NMR (acetone-d6): 8.87 1H), 8.48 Cdd, 1H), 7.99 (dt, 1H), 7.64 2H), 7.49 2H), 7.42 Cs, 1H), 7.40 Cm, 1H), 6.85 1H), 6.75-6.70 Cm, 2H), 4.70 (mn, 1H), 4.15 1H, OH), 4.01 2H), 3.74 3H), 1.70-1.50 Cm, 14H).
Example 111 SC H 3 171.9 0 C (decomposed) -69- WO 99/18099 WO 9918099PCT/CA98/00931 Example 112 Proton NMR (acetone 8.63 (dmn, 1H), 7.86 (td, 1H), 7.78 (dmn, 1H), 7.53 1H), 7.30-7.20 3H), 6.99 1H), 6.88 1H), 4.81 2H), 3.90 (s, 3H), 3.83 3H), 2.36 6H).
Example 113 'Proton NMR (acetone-d6): 7.63 2H), 7.50 2H), 7.26 1H), 6.88 (s, 1H), 4.48 1H), 4.41 2H), 4.06 1H), 2.31 6H), 1.52 6H), 1.50 6H).
WO 99/18099 WO 9918099PCT/CA98/00931 Example 114
F
F'
F
'Proton NMIR (acetone 8.45 (mn, 1H), 8.12 2H), 7.73 2H), 7.71 (mn, 1H), 7.59 2H), 7.44 1H), 7.30 1H), 7.14 (mn, 1H), 6.98 (d,2H, 4.56 2H), 3.83 3H).
Example 115
,CH
3 0
-CH
3 Proton NMR (acetone-d6): 8.09 2H), 7.61 2H), 7.41-7.38 (mn, 2H), 7.33 1H), 7.22-7.19 (mn, 2H), 7.08-7.04 (in, 2H), 7.01 1H)) 4.23 (s, 2H), 3.89 3H), 3.85 3H).
Example 116 150
-H
-71- 72 Proton NMR (acetone-d6): 8.10 2H), 7.66 2H), 7.36-7.34 2H), 7.31-7.18 5H), 7.00 1H), 4.27 2H), 3.89 3H), 3.84 3H).
Example 117
HCHO
0
\N
CH
3 'Proton NMR (acetone-d6): 8.57 2H), 7.76 1H), 7.59 2H), 7.26 1H), 7.15 (dd, 1H), 7.04 1H), 4.64 2H), 4.38 1H, OH), 3.87 (s, 3H), 3.86 3H).
Methods of Synthesis Examples *The compounds of the present invention can be prepared by the methods described below. It will be apparent to one skilled in the art that similar methodology could be used to prepare the enantiomers or the racemates of the illustrated compounds.
Method 1: A variety of organic acids (bromobenzoic acids, bromophenylacetic acids, 20 bromophenylpropionic acids, bromocinnamic acids, bromonicotinic acids, bromothiophenecarboxylic acids and bromofuroic acid, etc.) was loaded onto a Merrifield resin or a Wang resin according to known prior art [see: a) Gisin B.F.
(1973) Helv. Chim. Acta 56, 1476; b) Wang (1973) J Am. Chem. Soc. 95, 1382; c) Lu G. et al (1981) J. Org. Chem. 46,3433]. The palladium catalyzed crosscoupling reactions of these resin bound arylbromides with boronic acid 1 (the Suzuki reaction) were carried out according to the standard procedure described in the experimental to yield intermediates II (for a review of the Suzuki coupling reactions, see: Miyaura N. and Suzuki A. (1995) Chem. Rev. 95, 2457-2483; for an example of the Suzuki reaction on solid support, see: Frenette R. and Friesen R. (1994) Tetrahedron Lett. 35, 9177). Bromination of II with NBS (for an example of bromination of thiophene with NBS, see: Kellogg R. K. et al (1968) J. Org. Chem. 33, [R:\LIBAA]08614.doc:ACR WO 99/18099 PCT/CA98/00931 1902) in THF in the presence of water afforded the corresponding bromothiophene which was then subjected to another Suzuki reaction with arylboronic acids to furnish resins III. Reacting II with Br 2 PPh 3 gave the corresponding bromo resin IV (see: (1964) J. Am. Chem. Soc. 86, 964); IV were then treated with nucleophiles (thiols, amines, phenols, and boronic acids, etc.) to give resins V which were cleaved with TFA to furnish the correspong carboxylic acids Ia (Wang resin) or with MeMgBr to yield the corresponding dimethylcarbinols Ib.
-73- WO 99/18099 WO 9918099PCI'/CA98/00931 Method 1: General Method for Solid Phase Synthesis Br 0
OH
(HO)
2 1 Pd(Ph 3 4 Na 2
CO
3
DME
(H1) Merrifield or Wang Resin
NBS
X=H X=Br RaB(OH) 2 Na 2
CO
3 Pd(Ph 3 4
DUE
S
HXRbIBase (X NR', or RbB(OH) 2 XRbor R S
R
0
(V)
Ra Br 2 PPh 3
/CH
2 C1 2 0 (11) b or Rb I
I
Wang resin 0S Ra b
HO<
T FA 0o"* (Ia) oRb or Rb MeMgBr Wang or
I
Merrifield S Rb resin
OH
(1b) -74- WO 99/18099 PCT/CA98/00931 Method 2: The procedures for solution synthesis were similar to that described for the solid phase synthesis except that every intermediate was purified and characterized.
Additionally, the Heck coupling reactions (from intermediates VI to VII) were performed according to known literature procedures (for a review of the Heck reaction, see: de Meijere A. and Meyer F.E. (1994) Angew. Chem. Int. Ed. Engl. 33, 2379). Intermediates VII were reacted either with Br 2 PPh 3 to give the corresponding bromides- or with MsCI and diisopropylethylamine in THF to afford the corresponding mesylates which were then reacted with nucleophiles to furnish products Ic. alternatively, VII were reacted with compounds bearing an acidic OH group under the Mitsunobo reaction conditions (for a review, see: Hughes D.L. (1996) OrganicPreparations and Procedures Int. 28, 127-164) to yield products ID.
WO 99/18099 WO 9918099PCT/CA98/00931 Method 2: General Method for Solution Synthesis: x A Ka X =Br, I, OW Ara Ar and Het-Ar
OH
Pd(Ph 3 4 Na 2
CO
3 DM E 'Op AraB(OHb b b Aa S F (1c) Ii
OH
I I Aa a 01 (VI) NB S Ya=H-Ya=Br RaB(OH) 2 Na 2
CO
3 Pd(Ph 3 4
DME
or Ra R' Pd(Ph 3 2 C1 2 Et 3
N/DMF
1. Pd(Ph 3 4 Na 2
CO
3
DME
2. HC1 (1N),TH (P THP) 1 .Ph 3 PBr 2
/CH
2 C1 2 or MsC1Ii-Pr,NEt la 2. HYbRb/Base Yb S,NR' Both Ar a and Ra can be further modified to give derivatives
OH
Ara S Ra
(VII)
RbOH (M itsunobo reaction) 0,P Aa -S -Ra (Id) -76- WO 99/18099 PCT/CA98/00931 The invention will now be illustrated by the following nonlimiting examples in which, unless stated otherwise, all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: mm. Hg) with a bath temperature of up to 600C; the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only; melting points are uncorrected and indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations; the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data; yields are given for illustration only; when given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz or 400 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic signal; chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).
The example numbers below correspond to the example numbers (1-117) described above. Any examples listed above that are not mentioned or described below can be made by the combination of literature described methods and/or methods disclosed herein.
The following abbreviations have the indicated meanings: Ac acetyl Bn benzyl BSA bovine serum albumin cAMP cyclic -77wo 99/18099 WO 9918099PCT/CA98/00931 DBU DIBAL
DMA?
DMF
Et3N
GST
LDA in-CPBA-
MAMPP
MEPPM-
Ms MsO
NSAID-
o-Tol
OXONE®
PBS
PDC
PDE
Ph Phe
PMB-
Pye r.t.
rac.
SAM-
SPA
TBAF=
Th TFA
TFAA-
Thi
TLC-
1,8-diazabicyclo [5.4.01 undec-7-ene diisobutyl aluminum hydride 4-(diinethylamino)pyridine N,N-dimethylforinamide triethylamine glutathione transferase lithium diisopropylamide metachloroperbenzoic acid monoperoxyphtalic acid monoperoxyphthalic acid, magnesium salt 6H20 methanesulfonyl mesyl. SO2Me methanesulfonate mesylate non-steroidal anti-inflammatory drug ortho-tolyl 2KHS0 KHSO4 J2S04 phosphate buffer saline pyridinium chlorochromate pyridinium dichromate phosphodiesterase phenyl benzenediyl para-methoxybenzyl pyridinediyl room temperature racemi c aminosulfonyl or sulfonamide or S02NH2 scintillation proximity assay tetra-n-butylammonium fluoride 2- or 3-thienyl trifluoroacetic acid trifluoroacetic acid anhydride tetrahydrofuran thiophenediyl thin layer chromatography -78- WO 99/18099 WO 9918099PCTCA98OO93 1
TMS-CN
TNF
TZ
trimethylsilyl cyanide tumor necrosis factor 1H (or -79- WO 99/18099 WO 9918099PCT/CA98/00931 Alkyl Group Abbreviations Me methyl Et ethyl n-Pr normal propyl i-Pr isopropyl n-Bu normal butyl, i-Bu isobutyl s-Bu secondary butyl t-Bu tertiary butyl c-Pr cyclopropyl c-Bu cyclobutyl c-Pen cyclopentyl c-Hex cyclohexyl Dose Abbreviations bid bis in die qid quater in die tid ter in die twice daily four times a day.
three times a day WO 99/18099 PCT/CA98/00931 The following schemes illustrate intermediates to which reference is made in the description of the Examples.
Scheme 1: Resin Intermediates Br Resin A t= Wang Resin
OH
0 Resin C Resin B 0o Resin D Resin E Resin F Resin G -81- WO 99/18099 WO 99/ 8099PCT/CA98/00931 Scheme 2: Chemical Intermediates
'OH
OH
(HO)
2
B
,OMe 'OMe OMe OMe
OH
N. Br 8 EtO,
OH
~Si Br -82- WO 99/18099 WO 9918099PCT/CA98/0093
I
Scheme 2: Chemical Intermediates (continued) 12 13
.TMS
1S1rTMS 18 Br EtO N S B r 0 0-0 -83- WO 99/18099 WO 9918099PCT/CA98/00931 Experimental Example 2: 3-(4,6-Dimethylpyrimidin-2-yl)thiomethyl-2- [4-(1-hydroxy-1methylethyl)phenyll [2-(4-methylpiperazin- 1-yl)pyridlin-5-yl] thiophene A mixture of bromide 16 (257mg), lithium 2-(4-Nsalt (657mg), Pd(PPh 3 4 in DME/H 2 0 was heated to 800 overnight and worked up as usual. The crude product was purified by flash chromatography.
Eluting with 5% MeOH in CH 2 C1 2 afforded the title compound (80mg) as a white solid. 'H NMR: see Table 1.
Examples 9, 17, 20 and 24 were prepared similarly.
Example 3: 3-(4,6-Dimethvl imidin-2-vl')thiomethvl-2- 14-( 1-hvdroxv-1methvlethyl)phenvll f3-(4-priEdvyloxy)phenyll thiophene A mixture of Example 26 (48mg), 4-chlloropyridine (31mg) and K2CO, in DMAC was heated to reflux for 3h and cooled to rt. The mixture was diluted with water and extracted with ethyl acetate. The extract was washed with brine dried over MgSO 4 filtered and concentrated. The residue was purified by flash chromatography.
Eluting with 4:1 ethyl acetate in hexanes afforded the title compound (36mg, 64% yield) as a white solid. 'H NMR: see Table 1.
Examples 4 and 10 were prepared similarly.
Example 8: 2-(4-Carboxvphenyl)-5-(-3 .4-dimethoxvphenvl)-3-(4.6dimethylpyrimidin-2-yl)thiomethylthiophene Step 1. Preparation of Intermediate 2: To a solution of ethyl 4bromobenzoate (2.29g, l0mmol) in DME (4OmL) was added boronic acid 1 (2.37g, l5mnol), Pd(PPh 3 4 (346mg, 0.3mmol) and Na 2 C0 3 (2M, and the mixture was deoxygenated under a stream of N 2 for 5 min and then heated to 8000 for 50 min. After cooling to rt, the mixture was -84- WO 99/18099 PCT/CA98/00931 diluted with H 2 0 and extracted with ethyl acetate (3 x 50mL). The extracts were combined, washed with water, brine, dried over Mg 2
SO
4 and then filtered through a sintered funnel. The filtrate was concentrated in vacuo and the residue purified by flash chromatography (eluting with 40% ethyl acetate in hexanes) to afford intermediate 2 (2.7g, 100%) a yellow powder. 1 H NMR (400 MHz, CDC13): 88.07 2H), 7.56 (d, 2H), 7.33 1H), 7.20 1H), 4.69 2H), 4.28 2H), 1.62 1H, OH), 1.40 3H). This procedure will be referred to as the standard Suzuki coupling reaction conditions in solution.
Step 2. Bromination to Intermediate 3: To a solution of intermediate 2 (2.7g, 10mmol) in THF (50mL) at 0°C was added NBS (3.56g, and water (5mL) and the mixture was stirred at 0°C for 30 min and quenched with excess 5% Na 2 S20, aqueous solution. The mixture was then extracted with ethyl acetate (3 x 50mL) and the extracts combined, washed with water, brine, dried over Mg 2 SO, and filtered. The filtrate was concentrated in vacuo and the residue was purified by flash chromatography (eluting with 40% ethyl acetate in hexanes) to afford 3.24g (95% yield) of bromide 3 as a white crystalline solid after recrystallization from ether and hexanes. 'H NMR (400 MHz, CDC1,): 8 8.06 2H), 7.48 2H), 7.16 1H), 4.61 d, 2H), 4.38 2H), 1.75 1H), OH), 1.39 3H).
Step 3. Preparation of Intermediate 4: To a solution of bromide 3 (610mg, 1.79mmol) in DME (8mL) was added 3,4-dimethoxyphenylboronic acid (391mg, 2.15mmol) (see: Yokoe, I. et al, (1989) Chem. Pharm. Bull. 37, 529), Pd(PPh 3 4 (62mg, 0.054mmol) and Na 2 CO, (lmL, 2M) and the mixture was deoxygenated under a stream of nitrogen for 5 min, heated to reflux for 4h, and then cooled to rt and diluted with water. The mixture was then extracted with ethyl acetate (3x) and the extracts combined, washed with water, brine, dried over MgSO 4 filtered and concentrated to give the crude product which was purified by flash chromatography (50% ethyl acetate in hexanes) to yield compound 4 (0.65mg, 91% yield) as a yellow solid after recrystallization from ethyl acetate and hexanes. 1 H NMR (400MHz, Acetone-d 6 88.08 2H), 7.73 WO 99/18099 PCT/CA98/00931 2H), 7.48 1H), 7.25 1H), 7.21 (dd, 2H), 7.00 1H), 4.65 2H), 4.38 1H, OH), 4.37 2H), 3.90 3H), 3.85 3H), 1.38 3H).
Step 4. Preparation of Intermediate 5: To a solution of compound 4 (461mg, 1.16mmol) in CH 2 C1 2 (6mL) at 0°C was added Br 2 PPh, (586mg, 1.39mmol) and the solution was allowed to warm to rt and stirred for min under N 2 Then to the solution was added 4,6-dimethyl-2mercaptopyrimidine (325mg, 2.32mmol) and diisopropylethylamine (0.8mL) and the resultant solution was stirred at rt for lh and concentrated. The residue was purified by flash chromatography ethyl acetate in hexanes) to afford compound 5 (663mg, 91% yield) as a light yellow solid. 'H NMR (400 MHz, acetone-d 6 88.11 2H), 7.76 (d, 2H), 7.53 1H), 7.25 1H), 7.20 (dd, 1H), 6.99 1H), 6.90 1H), 4.50 2H), 4.37 2H), 3.90 3H), 3.84 3H), 2.33 6H), 1.38 3H).
Step 5. Hydrolysis: A mixture of compound 5 (213mg, 0.41 mmol) and LiOH (1.23mL, 1M) in dioxane (5mL) was heated to 80 0 C for 2h and cooled to rt, diluted with water and acetic acid and then extracted with ethyl acetate. The extract was washed with water, brine, dried over MgSO 4 filtered and concentrated. The crude was crystallized from ethyl acetate and hexanes to give the title compound as a white powdery solid (189mg, 94% yield). MP 238.80C.
Alternative method: Step 1. Preparation of Intermediate 6: To a solution of bromide 3 (111mg, 0.36mmol) dissolved in CH 2 C1 2 (2 mL) was added Br 2 PPh 3 (227mg, 0.54mmol) at 0°C and the mixture was stirred at 0°C under N 2 for lh. To the solution was added a solution of 4,6-dimethyl-2-mercaptopyrimidine in DMF (1M, 0.54mL) and diisopropylethylamine (93uL) and the mixture stirred at rt for 30 min, diluted with water and extracted with ethyl acetate. The extract was washed with brine, dried over MgSO 4 filtered and concentrated. The residue was purified by flash chromatograph ethyl acetate in hexanes) to give compound 6. 'H NMR (400 MHz, -86- WO 99/18099 WO 9918099PCT/CA98/00931 acetone-d 6 8 8.11 2H), 7.70 2H1), 7.33 1H1), 6.89 1H1), 4.45 (s, 2H), 4.39 2H), 2.31 6H), 1.36 3H).
Step 2. Preparation of Intermediate 5: Bromide 6 from above was reacted with 3,4-dimethoxyphenylboronic acid in a similar manner to that used to prepare compound 4, to yield compound Examples 27, 32, 34, 39, 42, 44, 49, 52, 54, 58, 59, 63, 73, 84, and 101 were prepared using technology similar to that described above.
Example 13: 5-(3 .4-Dimethoxyphenyl)-3-(4.6-dimethylpvrimidin-2vl)thiomethvl-2- f4-( 1-hvdroxv-1-methvlethvI)p~henyflthiophene To a solution of compound 5 (1.3g) in THF (l0mL) was added MeMgBr (10.3 mL, 1.4M in THF/Toluene) at 000 and the solution was stirred at At for 30 min and quenched with NH 4 C1 (sat'd aq) and extracted with ethyl acetate (2x5OmL). The extracts were combined, washed with brine, dried over MgSO 4 and filtered. Concentration of the filtrate gave a yellow residue which was purified by flash chromatography, eluting with ethyl acetate in hexanes. The title compound was crystallized from
CH
2 C1 2 and hexanes as a light yellow flaky solid (1.2g, 95% yield). M.P.: 71.50C; 1 H NMR (400MHz, acetone-d 6 87.64 2H), 7.55 2H), .47 (s, 1H), 7.22 1H), 7.18 (dd, 1H), 6.97 1H1), 6.88 1H), 4.46 2H), 4.09 1H1, OH), 3.88 3H1), 3.83 3H1), 2.33 611), 1.55 611).
Examples 38, 74, and 76 were prepared in a similar manner.
Example 18: 5-(3 .4-Dimethoxyphenvl)-3-(4,6-dimethvlpvrimidin-2vl)thiomethvl-2- 1-hydroxycvclobutyl)phenvll thiophene Step 1. One pot preparation of 4-trimethvlivpevbrnicai(se Kaufmnann et al, (1987) Chem. Ber. 120, 901): To a solution of pdibromobenzene (11.8g, 50mmol) in THF (250mL) at -780C was added n- BuLi (2OmL, 2.5M in hexanes) over 2 min and the mixture was stirred at -87 WO 99/18099 PCT/CA98/00931 -78 0 C for 2 min. TMSC1 (6.3mL, 50mmol) was added in one portion and the resultant mixture was stirred at -78 C for 10 min. n-BuLi was added again over 2 min and stirring was continued for 10 min at 78 0 C followed by the addition of triisopropylborate (13mL, quickly and the mixture was stirred at -780C for 30 min, allowed to warm to rt, quenched with water, AcOH (2.5 eq) and then extracted with ethyl acetate (3xlOOmL). The extracts were combined, washed with water and concentrated to afford 9g of the title boronic acid as a white solid which was further recrystallized from hexanes to give a grey white powder. 'H NMR (400MHz, acetone-d,): 57.85 2H), 7.53 2H), 7.11 [s, 2H, B(OH) 2 0.25 9H).
Step 2. Preparation of Intermediate 10 The boronic acid (4.96g, 25.5mmol) from Step 1 was reacted with 2-bromo-3hydroxymethylthiophene (4.7g, 24.3mmol) (prepared from 3thiophenemethanol with NBS in THF) under the standard Suzuki coupling conditions to yield intermediate 10 in 73% yield. 1H NMR (400MHz, acetone-d 6 87.62 2H), 7.54 2H), 7.39 1H), 7.21 1H), 4.62 2H), 4.17 1H, OH), 0.29 9H).
Step 3. Preparation of Intermediate 11 Compound 10 (4.6g, 17.5mmol) in THF (80mL) was treated with NBS (6.25g) at rt for 2h and quenched with 10% Na 2
S
2 ,O and then extracted with ethyl acetate. The extract was washed with water, brine, dried over MgSO 4 filtered and concentrated.
The residue was purified by flash chromatography (eluting with ethyl acetate in hexanes) to furnish 5.42g (90% yield) of bromide 11. 'H NMR (400MHz, acetone-d 6 67.62 2H), 7.49 2H), 7.23 1H), 4.57 (d, 2H), 4.31 1H, OH), 0.29 9H).
Step 4. Preparation of Intermediate 12 Bromide 11 (2g, 5.86mmol) was reacted with 3,4-dimethoxyphenylboronic acid (1.28g, 7mmol) under the standard Suzuki coupling reaction conditions to afford intermediate 12 (2.2g, 94% yield) as a white solid. 'H NMR (400MHz, acetone-d 6 87.63 (d, 2H), 7.57 2H), 7.44 1H), 7.25 1H), 7.20 (dd, 1H), 6.99 1H), 4.63 -88- WO 99/18099 PCT/CA98/00931 2H), 4.23 1H, OH), 3.90 3H), 3.84 3H), 0.30 9H).
Step 5. Preparation of Intermediate 13: Compound 12 (1.41g, 3.54mmol) was treated with a solution of IC1 (8.85mL, 1M in CH 2 C1l) at rt for lh and quenched with 10% Na 2 S20 3 The mixture was extracted with CH 2 C1 2 and the extract was concentrated. The residue was purified by flash chromatography (40% ethyl acetate, 10% CH 2 Cl 2 in hexanes) to give iodide 13 (1.3g, 81% yield) as a light brown solid. 'H NMR (400MHz, acetone-d 6 57.83 2H), 7.43 1H), 7.41 2H), 7.24 1H), 7.20 (dd, lh), 6.99 1H), 4.59 2H), 4.32 1H, OH), 3.89 3H), 3.83 3H).
Step 6. Preparation of Intermediate 14 To a solution of iodide 13 (Ig, 2.21mmol) in CH 2 C1 2 was added Br 2 PPh 3 (1.12g, 2.65mmol) and the mixture stirred at rt for 30 min. 4,6-Dimethyl-2-mercaptopyrimidine (619mg, 4.42mmol) and diisopropylethylamine (1.54mL) were introduced and the mixture was stirred at rt for lh, concentrated and the residue purified by flash chromatography (40% ethyl acetate in hexanes) to give compound 14 (1.28g, 100% yield) as a light yellow solid. 'H NMR (400MHz, acetone-d 6 57.86 2H), 7.49 1H), 7.42 2H), 7.23 1H), 7.18 (dd, 1H), 6.98 1H), 6.90 1H), 4.45 2H), 3.88 3H), 3.83 (s, 3H), 2.33 6H).
Step 7. To a solution of iodide 14 (68mg) and cyclobutanone (20PL) in ether (2mL) and THF (2mL) cooled to -100 0 C was added n-BuLi (O.llmL) and the mixture was allowed to warm to -70°C, quenched with water and extracted with ethyl acetate. The extract was washed with brine, dried over MgSO 4 filtered, concentrated and the crude was purified by flash chromatography (2:1 hexanes/ethyl acetate) to yield the title compound (52mg, 85% yield) as a white solid. 'H NMR: see Table 1.
Examples 25, 33, and 61 were prepared similarly.
Example 21: 5-(3.4-Dimethoxyphenvl)-3-(4.6-dimethylpyrimidin-2yl)thiomethyl-2-(4-methvlthiophenvl)thiophene -89- WO 99/18099 PCT/CA98/00931 Ste 1. Preparation of Intermediate 7: A mixture of thioanisolyl-4boronic acid (2.2g, 13mmol) (see: Santucci et al, (1958) J. Am. Chem. Soc.
193), 2-bromo-3-hydroxymethylthiophene THP ether (3g, 10.83nmol), Pd(PPh,) 4 (374mg, 0.324nmol) and Na 2
CO
3 (6.5mL, 2M) in DME (33mL) was deoxygenated under a stream of N 2 and heated to reflux overnight and worked up as usual. The crude product was purified by flash chromatography (10% ethyl acetate in hexanes) to afford 3.26g of coupling product 7. 1H NMR (400MHz, acetone-d 6 87.49 2H), 7.40 (d, 1H), 7.35 2H), 7.17 1H), 4.70 1H), 4.69 1H), 4.46 1H), 3.81 1H), 3.48 1H), 2.53 3H), 1.90-1.40 6H).
Step 2. Preparation of Intermediate 8: The product from Step 1 was dissolved in 50mL of THF/1N HC1 and heated to reflux for 3h and cooled to rt. To the mixture was then added NBS (4.53g) and the resultant solution stirred at rt for 2h and quenched with 5% Na 2
S
2 0, and then extracted with ethyl acetate (3 x 50mL). The extracts were combined, washed with water, brine, dried over MgSO 4 filtered and concentrated. The crude was purified by flash chromatography ethanol in ethyl acetate) to yield 1.8g of sulfoxide 8. 1H NMR (acetone-d 6 400MHz): 87.78 2H), 7.71 2H), 7.28 1H), 4.59 2H), 4.43 (bt, 1H, OH), 2.90 3H). Alternatively, the same compound was prepared from the reaction of boronic acid 1 and 4-bromothioanisole under the Suzuki coupling reaction conditions and the resultant product brominated in a similar manner as described.
Step 3. Preparation of Intermediate 9. To a solution of sulfoxide 8 (1.8g, 6mmol) in CH 2 C1 2 (40mL) was added BrPPh 3 (5.08g, 12mmol) at rt and the mixture stirred at rt for lh. To the mixture was then added 4,6dimethyl-2-mercaptopyrimidine (2.52g, 18mmol) and diisopropylethylamine (5.2mL, 30mmol) and the mixture stirred at rt for lh and concentrated. The residue was purified by flash chromatography to yield compound 9 as a white solid (2.3g, 88% yield). 'H NMR (400MHz, acetone-d): 57.48 2H), 7.37 2H), 7.27 1H), 6.89 1H), 4.40 (s, 2H), 2.54 3H0, 2.33 6H).
WO 99/18099 PCT/CA98/00931 Step 4. A mixture of 9 (700mg, 1.6mmol), 3,4-dimethoxyphenylboronic acid (350mg, 1.92mmol), Pd(PPh 3 4 (55mg, 0.048mmol) and Na 2
CO,
(ImL, 2M) in DME (5mL) was heated to reflux for 2h and worked up as usual. The crude product was purified by flash chromatography ethyl acetate in hexanes) to yield the title compound (711mg, 90% yield) as a yellowish solid after crystallization from CH 2 Cl1~hexanes. 'H NMR: see Table 1.
Examples 4, 7, 15, 24, and 28 were prepared similarly by reacting intermediate 9 with the appropriate boronic acids and further modifications.
Example 26: 3-(4.6-Dimethvlpyrimidin-2-yl)thiomethyl-2-[4-(1-hydroxy-1methylethyl)phenyl-5-(3-hydroxyphenyl)thiophene Step 1. Preparation of Intermediate 15: To a solution of compound 2 (4g) in THF (80mL) was added MeMgBr (51mL, 3M in THF) in THF at 0°C under N 2 and the resulting mixture was stirred at that temperature for 1 h, quenched with 1N HC1 and extracted with ethyl acetate. The crude was purified by flash chromatography (2:1 hexanes/ethyl acetate) to give 3g of product 15. 1H NMR (400MHz, acetone-d 6 57.60 2H), 7.49 2H), 7.36 1H), 7.20 1H), 4.61 (d, 2H), 4.15 1H, OH), 4.05 1H, OH), 1.54 6H).
Step 2. Preparation of Intermediate 16: Compound 15 (3.0g) was dissolved in THF (100mL) and cooled to 0°C. To the solution was added NBS (4.3g) and H 2 0 (lmL) and the mixture stirred at 00C for lh, quenched with Na 2
S
2 03 and NaHCO and extracted with ethyl acetate.
The crude product was purified by flash chromatography (2:1 hexanes/ethyl acetate) to yield bromide 16. 'H NMR (400MHz, acetoned 6 57.62 2H), 7.44 2H), 7.20 1H), 4.58 2H), 4.30 1H, OH), 4.10 1H, OH), 1.55 6H).
Step 3. Preparation of Intermediate 17: To a solution of bromide 16 (2.6g) in THF (10mL) and CHC1 2 (10mL) at 0°C was added MsCI (0.54mL) and -91- WO 99/18099 PCT/CA98/00931 diisopropylethylamine (1.33mL) and the mixture was stirred at 00C for 2h. 4,6-Dimethyl-2-mercaptopyrimidine (1.36g) was added followed by diisopropylethylamine (3.63mL) and the mixture was stirred for an additional 15 min at 0°C and then at rt for 20 min. Concentration in vacuo afforded the crude product which was purified by flash chromatography (2:1 hexanes/ethyl acetate). Compound 17 (2.8g, 82% yield) thus obtained exists as a white solid. 'H NMR (300MHz, acetoned 6 57.64 2H), 7.48 2H), 7.26 1H), 6.86 1H), 4.41 2H), 4.10 (s, 1H, OH), 2.31 6H), 1.54 6H).
Step 4. Example 26: A mixture of the bromide 17 (983mg), 3-allyloxyphenylboronic acid (623mg, prepared by reacting 3-bromophenol allyl ether with n-BuLi and triisopropylborate), Pd(PPh3) 4 (81mg) and Na 2
CO,
(2.3mL, 2M) in DME was deoxygenated under nitrogen and then heated to reflux overnight. The mixture was cooled to rt and worked up as usual. To the crude product dissolved in THF (10mL) was added Pd(PPh 3 4 (85mg) and pyrrolidine and the mixture was degassed under nitrogen and heated to reflux for lh, cooled to rt, acidified with 1N HC1 and extracted with ethyl acetate. The crude product thus obtained was purified by flash chromatography (1:1 hexanes/ethyl acetate) to yield the title compound as a white solid. 'H NMR: see Table 1.
Example 35: 2-(4-Carboxyphenvl)-5-(3-cvclopentyloxv-4-methoxyphenvl)- 3-(4.6-dimethylpyrimidin-2-vl)thiomethvlthiophene Step Preparation of 3-hvdroxymethvlthiophene-2-boronic acid To a solution of 2-(dihydroxyboranyl)thiophene-3-carboxaldehyde (prepared from thiophene-3-carboxaldehyde dimethyl acetal by a modified literature procedure, see: Gronowitz, S. et al, (1967) Acta Chem. Scand.
21, 2151) (3.34g, 0.214mol) in ethanol (20mL) at 0°C under nitrogen was added NaBH 4 (0.81g, 0.21mol) in portions in 10 min. After stirring for min at 0°C, the mixture was quenched with water and NH 4 C1 (sat'd aq.).
The pH was adjusted with 1N HC1 -5-6 and the mixture was extracted with ethyl acetate (5 x 30mL). Evaporation of the extracts afforded the title compound as a white powdery solid (3.5g, 100%): 1 H NMR (400MHz, -92- WO 99/18099 PCT/CA98/00931 Acetone-d 6 1 drop D 2 57.52 1H), 7.03 1H), 4.78 2H). The product was kept under nitrogen at -20 0 C to avoid decomposition.
Step 2. Preparation of Resin B: Reaction of 1 with polymer bound (Wang resin) 4-bromobenzoate (resin To a suspension of the resin (6.16g, 5.3 mmol, 0.86mmol/g loading) in DME (30mL) was added boronic acid 1 (1.67g, 10.6mmol), Pd(PPh 3 4 (184mg, 0.16mmol) and Na 2
CO
3 (2M solution, 5.3mL) and the mixture was deoxygenated under a stream of nitrogen for 5 min under gentle stirring and then heated to 850C under nitrogen overnight. The mixture was filtered when hot and the resin washed sequentially with DMF DMF/H20 DMF THF (2x) and then MeOH (3x) and dried under nitrogen flow for 48 h to yield resin
B.
Step 3. Preparation of Resin C: Resin B was suspended in 60mL of THF and cooled to 0°C. NBS (1.9g, 10.6mmol) was added followed by lmL and the mixture was allowed to warm to rt for 11/2 h and filtered. The resin was then washed with THF DMF THF (2x) and MeOH (3x) and dried under nitrogen and then under vacuum to give resin C.
Step 4. Preparation of 3-Cyclopentvloxy-4-methoxyphenvlboronic acid: To a solution of 4-bromo-2-cyclopentyloxy-l-methoxybenzene (3.4g, 12.5mmol) (see: Meyer, A. I. et al, (1993) J. Org. Chem. 58, 36) in THF at -780C was added n-BuLi (5.2mL, 2.4M in hexanes) over 2 min and the resultant solution stirred at -78 0 C for 5 min. Triisopropylborate (3mL) was added in one portion and the mixture was stirred at -780C for min, allowed to warm to rt, and quenched with water and acetic acid (0.75mL). Concentration in vacuo afforded a white solid which was filtered. The white solid was washed twice with water and dried under reduced pressure to give the title compound (2.64g, 89% yield) as a white powder. 'H NMR (400MHz, acetone-d, 1 drop D 2 57.44-7.41 2H), 6.90 1H), 4.80 1H), 3.77 3H), 1.90-1.50 8H).
-93- WO 99/18099 PCT/CA98/00931 Step 5. Preparation of Resin D: General procedure for the Suzuki coupling reaction on solid support: A suspension of resin C (2.76g), 3cyclopentyloxy-4-methoxy-phenylboronic acid (1.56g, 6.6mmol), Pd(PPh,) 4 (77mg, 0.066mmol) and Na2CO, (2M, 3mL) in DME (27mL) was deoxygenated under a stream of nitrogen for 5 min and then heated to reflux for 7 h and poured into a 70 mL fritted polypropylene tube. The solvents were flushed out with a stream of nitrogen and the resin washed sequentially with DMF (3x) DMF/H 2 O DMF THF (2x) and MeOH (3x) and then dried under nitrogen overnight to afford 2.9g of resin D.
Step 6. Preparation of Resin E: Converting CH 2 OH to CH 2 Br: To a suspension of resin D (2.9g) in dichloromethane (30mL) under N, at 0°C was added Br 2 PPh, (1.5g, 3.48mmol) and the mixture was allowed to warm to rt with gentle stirring and then filtered. The residual resin was washed with CH 2 C1 2 THF ethyl acetate (2x) and ether (3x), and dried under reduced pressure to give resin E.
Ste 7. Final product: To a suspension of resin E (50mg) in DMF in a 5-mL fritted polypropylene tube equipped with a Teflon stopcock was added a solution of 4,6-dimethyl-2-mercaptopyrimidine in DMF( 200pL, 1M) and diisopropylethylamine (50pL) and the mixture was shaken for 1 h at rt. The solvent was drained and the residue washed with DMF THF MeOH (3x) and CH 2 C1 2 (3x) and the resultant resin was then treated with lmL 20%TFA in CH 2 C1 2 (containing dimethyl sulfide) for 30 min. The liquid was drained to a round bottom flask and the residual resin washed with CH 2 C1 2 (3x) and again drained to the flask. Evaporation of volatiles afforded the title compound as a yellow solid. 'H NMR: see Table 1.
S Examples 27, 82, 83, 86, 94, 95, 96, 97, 100, 102, 103, 104, 108, 114, 115, and 116 were prepared similarly.
Examples 14, 40, 43, 48, 50, 78, 80, 81, 85, 87, 89, and 90 were synthesized from the corresponding polymer (Merrifield or Wang resins) bound -94- WO 99/18099 PCT/CA98/00931 bromides according to similar procedures as described for Example except for the cleavage. The Cleavage were carried out using MeMgBr (1.4M in THF/toluene, 20eq) in THF at room temperature for 2-12h and filtered through fritted polypropylene reservoirs. The filtrates were quenched with NH 4 C1 (saturated aq.) and extracted with ethyl acetate.
The crude products were purified by preparative TLC.
Example 106: 5-(4-Carboxyphenyl)-2.3-bis((3-cyclopentyloxy-4methoxy)phenyl)thiophene Step 1. Preparation of boronic acid 18: To a solution of 3-trimethylsilylthiophene (1.56g) in THF (15mL) at -780C was added a THF solution of LDA (pre-prepared from 1.68mL of diisopropylamine and 4.6mL 2.4M n- BuLi in THF) via a cannula and the resultant solution was stirred at 780C for 10 min, rt for 30 min and cooled to -78 C again.
Triisopropylborate (1.37mL) was added and stirring was continued for lh at -78 0 C and rt for 30 min. The mixture was then quenched with H 2 0 and partitioned between hexanes and H 2 0. The aqueous phase was acidified with acetic acid to pH-5 and extracted with ethyl acetate (3x).
The extracts were concentrated and the crude was recrystallized from to yield 18 (1.41g) as a white powder. 'H NMR (400MHz, acetone-d): 57.79 2H), 7.25 (bs, 2H), 0.25 9H).
Step 2. Preparation of Intermediate 19 A solution of ethyl 4bromobenzoate (460mg), boronic acid 18 (500mg), Pd(OAc) 2 (13.5mg), PPh 3 (32mg) in DMF (3mL) and Et3N (3mL) was heated to 900C overnight and cooled to rt. The mixture was diluted with water and extracted with ether The extracts were combined, washed with water, brine, dried over MgSO and concentrated. The residue was purified by flash chromatography ethyl acetate in hexanes) to give compound 19 (584mg) as a yellow oil. 1H NMR (400MHz, CDC13): 88.02 2H), 7.66 (d, 2H), 7.42 1H), 7.41 1H), 4.37 2H), 1.39 3H), 0.28 9H).
Step 3. Preparation of Intermediate 20: A solution of 19 (470mg), NBS (550mg) and AcOH (ImL) in THF was heated to reflux for 2h and cooled WO 99/18099 PCT/CA98/00931 to rt. The mixture was treated with aqueous Na 2
S
2 0, and extracted with ethyl acetate. The extract was concentrated and the crude purified by flash chromatography to give compound 20. 1 H NMR (CDC1,, 400MHz): 88.05 2H), 7.53 2H), 7.18 1H), 4.36 2H), 1.40 3H).
f- Step 4. A mixture of 20 (303mg), 3-cyclopentyloxy-4methoxyphenylboronic acid (373mg), Pd(PPh,) 4 (27mg) and Na 2 CO(0.8mL, 2M) in DME (7mL) was deoxygenated under N 2 and heated to reflux for 5h and worked up as usual. Purification of the crude by flash chromatography failed to give compound 21 in its pure form. As a result, the fraction containing 21 (180mg) was dissolved in dioxane (ImL) and H20 (lmL) containing LiOH monohydrate (46mg) and the mixture was heated to 70 0 C for 2h and cooled to rt. The mixture was acidified with 1N HC1 and then extracted with ethyl acetate. The crude product was purified by flash chromatography (60% ethyl acetate, ethanol in hexanes) to afford the title compound. see Table 1.
Example 110: 3-(3-Cvclopentvloxy-4-methox)benzyl-2-[4-(1-hvdroxy-1methylethyl)phenyll-5-(3-pyridin-1-yl)thiophene Step 1. Preparation of Resin F: A suspension of resin C lithium pyridine-3-trimethylboronate (1.81g) (see: Fischer et al, (1974) Recl. Tray.
Chim. Pays-Bas 93, 21) and Pd(PPh 3 4 (199mg) in DME (32mL) and H 2 0 (4mL) was deoxygenated under N 2 for 5 min and then heated to reflux overnight. The mixture was filtered and the residue washed with DMF
DMF/H
2 0 THF CH 2 C1 2 (2x) and MeOH (3x) and dried under reduced pressure to yield resin F.
Step 2. Preparation of Resin G: To a suspension of resin F (4.3g) in
CH
2 C1 2 (30mL) was added Br 2 PPh, (2.18g) and the suspension was stirred at rt for lh and filtered. The residue was washed with CH 2 Cl 2 DMF THF(2x), ethyl acetate (2x) and ether and then dried under reduced pressure to afford resin G.
-96- WO 99/18099 PCT/CA98/00931 Step 3. A mixture of resin G (96mg), 3-cyclopentyloxy-4-methoxyphenylboronic acid (54mg), Pd(PPh 3 4 (4.4mg) and CsF (70mg) was deoxygenated under N 2 for 5 min and heated to 80C for 2h. The mixture was filtered when hot and the residue washed with DMF DMF/H 2
O
DMF, THF (2x) and MeOH (3x) and then dried under reduced pressure. To the dried resin suspended in THF (lmL) was added MeMgBr (lmL, 1.4M in THF/Toluene) and the mixture was stirred at rt for 2h. The mixture was filtered and the residue washed twice with
THF/H
2 0 The filtrate and the washing solutions were combined, quenched with NH 4 C1 (aq) and extracted with ethyl acetate The extracts were concentrated and the residue purified by preparative TLC to yield the title compound. 'H NMR: see Table 1.
Assays for Determining Biological Activity Establishment of CHO-K1 cell lines stably expressing PDE IVa enzyme CHO-K1 cells stably expressing the prostacyclin receptor and grown under G418 selection as described previously Boie, et al, J. Biol. Chem.: 269, 12173-12178, 1994) were plated at a density of 1.75 x 106 cells/175cm 2 in a T-175 flask (Gibco, Burlington, VT) containing alpha MEM media; 10% heat inactivated fetal bovine serum (FBS); 1% penicillin/streptomycin; 25 mM Hepes, pH 7.4; and 500 gg/ml G418 (complete media). The cells were placed in an incubator for 24 hr at 37°C and 5% CO2. The cells were then washed with warmed sterile phosphate buffered saline (PBS) and incubated with 2gg/ml DNA, and 9 gg/ml lipofectamine reagent in Opti-MEM for 7 hr. At 37°C and 5% CO 2 The incubation solution was diluted 1:2 with Opti-MEM containing FBS and incubated overnight. Following the overnight incubation, the media was replaced by complete media containing 500 gg/ml hygromycin B. Colonies were identified and grown in T-175 flasks for further characterization.
Measurement of whole-cell cAMP content CHO-K1 cells were plated at a density of 10 6 cells/175 cm 2 containing complete media with 500 gg/ml hygromycin. The flasks were -97- WO 99/18099 PCT/CA98/00931 maintained in an incubator at 37 0 C with 5.0% CO 2 for 72 hr. The media was changed and the cells were allowed to grow overnight. The cells were washed and dissociated from the plate with PBS containing 0.5 mM EDTA. Cellular cAMP content was.measured by centrifuging the cell suspension at 150 g x 10 min. And resuspending the cells in a Hanks buffered salt solution at a density of 0.2 x 106 cells/ml. The cells were preincubated at room temperature for 15 min. and then incubated with jgM prostaglandin 12 (PGI 2 and the indicated compound for an additional 10 min. Basal cAMP levels were determined by incubating the cells in 0.1% DMSO. The incubations were terminated by the addition of HCl (0.1 N final) and the cells measured for cAMP as described below.
Determinations of whole-cell cAMP content were performed by incubating 100 pl reconstituted rabbit anti-succinyl cAMP serum with 100 pl of the whole-cell reaction or known cAMP standard and 30 pmol of 12I-cAMP TME in a ScintiStrip T well (300 pl final volume) at room temperature for 18 h. Total cpm (Bo) was determined in the absence of sample of cAMP standard. The reaction mixture was then aspirated out of the well, and the individual wells were counted in a Beckman LS 6000SC with the window open from 10-999 for 1 min. The data were expressed as %B/Bo [(standard or sample cpm non-specific cpm) (Bo cpm non-specific cpm)] x 100. Non-specific cpm were determined by incubating only the 125 I-cAMP TME with assay buffer (50 nM acetate; pH 5.8) in the ScintiStripTM well. All determinations were performed in triplicate.
The Elevation of cAMP in Leukocytes The effect of compounds of the invention on intracellular cAMP was investigated using human neutrophils or guinea pig eosinophils. Human neutrophils were separated from peripheral blood, incubated with dihydrocytochalasin B and the test compound for 10 min and then stimulated with FMLP. Guinea pig eosinophils were harvested by peritoneal lavage of animals previously treated with intraperitoneal injections of human serum. Eosinophils were separated from -98- WO 99/18099 PCT/CA98/00931 the peritoneal exudate and incubated with isoprenaline and test compound. With both cell types, suspensions were centrifuged at the end of the incubation, the cell pellets were resuspended in buffer and boiled for 10 min prior to measurement of cAMP by specific radioimmunoassay (DuPont).
The most potent compounds according to the invention induced a concentration-dependent elevation of cAMP in neutrophils and/or eosinophils at concentrations of 0.lnM to 1M.
Human Whole Blood Assay Fresh blood was collected in heparinized tubes by venipuncture from healthy volunteers. These subjects had no apparent inflammatory conditions and had not taken any NSAIDs for at least 4 days prior to blood collection. Five hundred pL aliquots of human blood were initially pre-incubated at 37 0 C with either 2 iL DMSO (vehicle) or 2 pL of a test compound at a final concentration of up to 100 RM. Fifteen min later, the blood was incubated with lipopolysaccharide (LPS) at 1 gg/ml (Sigma Chem, #L-2630 from E. coli, serotype 0111:B4; diluted in 0.1% w/v BSA/PBS) for 24 h at 37 0 C. At the end of the 24 h incubation, the blood was further incubated with an additional amount of LPS (final concentration: 1 gg/ml) for 30 min at 37 0 C. This was followed by incubation with n-formyl-Met-Leu-Phe (f-MLP) at 1 RM (Sigma Chem, F- 3506, diluted in 1% w/v BSA/PBS) for 15 min at 37 0 C. The blood was immediately centrifuged at 4 0 C for 10 min. at 3,300 rpms to obtain plasma. A plasma aliquot was diluted in PBS and assayed for TNF-a using a commercial ELISA kit (Cistron). An additional plasma aliquot was de-proteinized with methanol and the supernatant was assayed for
LTB
4 using a commercial EIA kit (Cayman).
The instant compounds showed IC 5 o values ranging from 1 nM to 5 pM.
Human Mononuclear Cell Assay Fresh blood was collected from healthy volunteers by venipuncture into tubes containing 0.13M sodium citrate as anticoagulant (final 10%v/v in blood). The blood was diluted in equal parts with PBS and gently layered on top of one half volume histopaque -99- WO 99/18099 PCT/CA98/00931 (1.077 density) and was centrifuged at 1400 rpm for 35 min at room temperature. After centrifugation, a distinct layer of mononuclear cells (monocytes and lymphocytes) located between the blood and histopaque layers could be aspirated off using a transfer pipette. The mononuclear cells were washed in calcium and magnesium free PBS. The cell pellet was resuspended in RPMI 1640 (Gibco BRL) complete media (containing streptomycin/penicillin and HEPES buffer) at a cell density of 1 x 106 cells/ml. Two hundred .1 aliquots of mononuclear cells were mixed with 2 .1 of DMSO (vehicle) or a test compound at a final concentration of up to 10 gM in the presence of 1% or 25% heat-inactivated human serum.
Fifteen min. later, the cells were incubated with LPS at a final concentration of 1 gg/ml at 370C for 20 h. At the end of the incubation period, the supernatant was obtained by centrifugation at 1000 rpm for min and was assayed for TNF-a using a commercial ELISA kit (Cistron).
The instant compounds showed IC 5 0 values ranging from 0.1 nM to 5 M.
In Vivo inhibition of allergen induced bronchoconstriction Guinea pigs, 200 g, are sensitized with a 100g/ml ovalbumin in an A1 2 0 3 suspension in physiological saline. Five hundred p1 of this solution are injected intraperitoneally and another 500 il are injected in 6 ganglionic regions ±75 pl/site). The animals are then housed for 4 to 6 weeks. Thirty minutes prior to the experimentation, the guinea pigs are treated with the test compound or vehicle and with mepyramine maleate, 1 mg/kg. The injection volume is 1 ml/kg of body weight.
After pre-treatment, the animals are placed in a whole body plethysmograph for conscious unrestrained guinea pigs. The animals are challenged for one minute with an aerosol containing ovalbumin in a concentration of 1% in physiological saline. The changes in pulmonary function assessed as changes in enhanced pause or Penh. Penh, a marker of bronchoconstriction, is defined as follows: Penh=[(expiratory time/relaxation time)-l]*[(peak expiratory flow/peak inspiratory flow] -100- WO 99/18099 PCT/CA98/00931 The results are expressed as the percentage of inhibition of the Penh increase versus the response obtained in a control experiment.
SPA based PDE activity assay protocol for measuring inhibition of Phosphodiesterase activity Compounds which inhibit the hydrolysis of cAMP to AMP by the type-IV cAMP-specific phosphodiesterases were screened in 96well plate format as follows: In a 96 well-plate at 30 oC was added the test compound (dissolved in 2 ul DMSO), 188 g1 of substrate buffer containing [2,8-3H] adenosine 3',5'-cyclic phosphate (cAMP, 100 nM), 10 mM MgC12, 1 mM EDTA, 50 mM Tris, pH 7.5. The reaction was initiated by the addition of ll of human recombinant PDE-IV isozymes, either expressed and purified from sf9 cells, or from CHO-K1 cells (the amount was controlled so that 10% product was formed in 10 min. at 30 oC). The reaction was stopped after 10 min. by the addition of 1 mg of PDE-SPA beads (Amersham). The product AMP generated was quantified on a Microbeta 96-well plate counter. The signal in the absence of enzyme was defined as the background. 100% activity was defined as the signal detected in the presence of enzyme and DMSO with the background subtracted. Percentage of inhibition was calculated accordingly. The value was approximated by the non-linear regression fitting of a ten point titration using the standard 4 parameter equation.
values were determined with 100 nM cAMP using the purified GST fusion protein of the human recombinant phosphodiesterase IVa (met-248) produced from a baculovirus/Sf-9 expression system. The instant compounds were shown to have ICso values of 0.01 to 1000 nM.
-101- Il V.3 V1 Yvrfl 10 '40 rJ1A 01 VC Uf-OJ.)33VJ
UU
I -r tlU0lAALlA Lf/j V u z EDITORIAL
NOTE:
CASE FILE NO.: 193347/98 (732406) THIS SPECIFICATION DOES NOT CONTAIN PAGE NUMBER 102.
21 MAR '01 15:48 21 MA '01 5:4861 02 62853593 PAGE. 002

Claims (4)

  1. 3- 20066 j) -CO 2 C 1 3 alkyl or -C0 2 C 3 cycloalkyl, k) -CH=CH-C(Me) 2 0H, 1) -CONR 4 R M) -S(O) 2 NR R', n) tetrazol-5-yl, or .fo) -CH=N-O-CH 2 CO 2 H, R' is-_X-~Y-Ar2, wherein: X'I is -CH 2 and Y' is Ar 2 is an aromatic ring selected from phenyl, naphthyl, pyimidinyl, pyridinyl or thienyl, optionally substituted with up to two substituents chosen independently among: 1) C 16 alkyl or C 3 6 cycloalkyl, 2) C 1 6 alkoxy or C 3 cycloalkyl, 3) -OH, 4) halo, or CF 3 R 2is selected from: a) hydrogen or b) C 1 3 alkyl or C 3 cycloalkyl, R 3 is selected from phenyl, naphthyl, pyridinyl, fliryl, thienyl or ethinyl, optionally substituted with up to two substituents chosen independently among: a) C 1 3 alkyl or C 3 cycloalkyl, b) C 1 3 fluoroalkyl or C 3 fluorocycloalkyl, C) C 1 6 alkoxy or C3- 6 cycloalkyloxy, d) C 13 fluoroalkoxy or C 3 fluorocycloalkoxy, )-104-Sa" 20066 e) C 13 alkylthio or C 3 cycloalkyithia, f)halo, g)-OH, h) -NO 2 i) -CH 2 OH, j) -NI{COKR 9 R' 0 112 k) -S(O 2 N' R 1) -SCH 2 1,1 -c-Pr)CH 2 CO 2 H, m) I1-piperazinyl, optionally substituted with C 13 alkyl, n) 4-morpholinyl, or o) -X 2 -y 2 -Ar 3 wherein, X2 IS 1) -CHI-, 2) or 3) a bond; y2 is 1) or 3) a bond; Ax 3 is phenyl, pyridinyl, pyrimidinyl or pyrazinyl, optionally substituted with up to two substituents chosen independently among: 1) C 1 3 alkyl or C 3 cycloalkyl, optionally substituted with -OH, or 2) -CH 2 CO 2 H; R 4 and R 5 are independently selected from: a) hydrogen, b) C 1 3 alkyl, C) -S(O) 2 CI- 3 alkyl or -S(O) 2 C 3 cycloalkyl, or y
  2. 105-I 20066 d) -S(O) 2 phenyl, optionally mono-substituted with Cl.3alkyl or C 3 cycloalkyl, Ci.3alkoxy or C 3 cycloalkyloxy, Cl.3alkylthio or C 3 cycloalkylthio or halo; R 6 and R 7 are independently chosen from among: a) hydrogen, b) Cl4alkyl or C34 cycloalkyl, c) -CO-Ci-4alkyl, or d) -CO-phenyl, optionally mono-substituted with CC_ 3 alkyl or C 3 -6 cycloalkyl, Cl.3alkoxy or C 3 cycloalkyloxy, Cl_ 3 alkylthio or C 3 cycloalkylthio or halo; R S is chosen from among: a) hydrogen, or b) C 15 saikyl or C 3 -5 cycloalkyl; R 9 and R10 are independently chosen from among: a) hydrogen, b) C 1 _4alkyl or C 3 4 cycloallkyl, or c) phenyl; and R" and R 1 2 are independently chosen from among: a) hydrogen, b) Cisalkyl or C 3 -5 cycloalkyl. 2. A compound according to Claim 1 wherein R 2 is hydrogen. -106- ,u 20066 3. A compound according to Claim 1 wherein: Ar 2 is pyrimidinyl, optionally substituted with up to two substituents chosen independently among: 1) C 1 6 alkyl or C 3 6 cycloalkyl, 2) C 1 6 alkoxy or C 3 6 cycloalkyloxy, 3) -OH, or 4) halo, and the remaining substituents are defined as in Claim 1. 4. A compound according to Claim 1 wherein: Ar' is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) C 1 6 alkyl or C 3 6 cycloalkyl, optionally substituted with -OH, -CO 2 H, CO 2 C 1 -3alkyl, C0 2 C 3 cycloalkyl and CN, b) C 1 3 alkoxy or C 3 cycloalkyloxy, c) C 1 3 alkylthio or C 3 cycloalkylthio, d) C 3 alkylsulfinyl or C 3 cycloalkylsulfinyl, e) C 3 alkylsulfonyl or C 3 cycloalkylsulfonyl, f) C 3 fluoroalkyl or C 3 fluorocycloalkyl, g) halo, h) -OH, i) -CO 2 H, j) -CO 2 C1- 3 alkyl or -C0 2 C 3 cycloalkyl, Ar2 is pyrimidinyl optionally substituted with up to two substituents chosen independently among: 1) C,- 6 alkyl or C 3 6 cycloalkyl, LU 20066 2) C 16 alkoxy or C 3 6 cycloalkyloxy, 3) -OH, or 4) halo, R 2 is hydrogen; R 3 is selected from phenyl, naphthyl, pyridinyl, furyl or thienyl, optionally substituted with up to two substituents chosen independently among: a) CI- 3 alkyl or C 3 cycloalkyl, b) C 1 3 fluoroalkyl or C 3 fluorocycloalkyl, C) C 1 6 alkoxy or C 3 6 cycloalkyloxy, d) CI- 3 fluoroalkoxy or C 3 fluorocycloalkyl, e) C 1 3 alkylthio or C 3 cycloalkylthio, f)halo, g) -OH, h) -NO 2 i) -CHOH, j) -N}{C0NR'R 1 k) -S(O) 2 NR 1 R 12 1) -SCH 2 (l,1-c-Pr)CH 2 CO 2 H, or M) -X 2 -Y 2 -Ar 3 wherein, X, is 1) -CH 2 2) or 3) a bond; y 2 is )O 2) or 3) a bond; Ar 3 is phenyl, pyridinyl, or pyrimidinyl optionally substituted with up to two substituents chosen independently among: ?I LU l 108 20066 1) C 1 3 alkyl or C 3 cycloalkyl, optionally substituted with -OH, or 2) -CCH 2 CO 2 H; R 4 and R 5 are independently selected from: a) hydrogen, b) C 13 alkyl or C 3 cycloalkyl, c) -S(0) 2 Cl-3alkyl or -S(0) 2 C 3 cycloalkyl, or R6 and R 7 are independently chosen from among: a) hydrogen, b) Cl-4alkyl or C 3 -4cycloalkyl, c) -CO-CI 4 alkyl, -CO-C 3 4 cycloalkyl, or R8 is chosen from among: a) hydrogen, or b) C 1 -salkyl or C 3 5 cycloalkyl, R9 and R1o are independently chosen from among: a) hydrogen, b) C 1 4 alkyl or C 3 4 cycloalkyl, and R" and R' 2 are independently chosen from among: a) hydrogen or b) C 1 -salkyl or C 3 -cycloalkyl. A compound according to claim 1 wherein Ar' is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) CI-alkyl or C 3 .6cycloalkyl, optionally substituted with -OH, -CO 2 H, CO 2 C 1 -3alkyl or -C0 2 C 3 cycloalkyl and CN, -109- 20066 b) c) d) e) f) g) h) i) j) R' is -x'-Y'-Ar 2 wherein: C 1 3 alkoxy or C 3 cycloalkyloxy, CI- 3 alkylthio or C 3 cycloalkylthio, CI- 3 alkylsulfinyl or C 3 cycloalkcylsulfinyl, CI- 3 alkylsulfonyl or C 3 cycloalkylsulfonyl, C 1 3 fluoroalkyl or C 3 fluorocyccloalkyl, optionally substituted with -OH, halo, -OH, -CO 2 H, -CO 2 CI- 3 alkyl or -CO 2 C 3 cycloalkyl, is CH 2 S; Ar 2 is pyrimidinyl optionally substituted with up to two substituents chosen independently among: 1) C 1 6 alkyl or C 3 6 CYCloalkyl, 2) C 1 6 allcoxy or C 36 cycloalkyloxy, 3) -OH, or 4) halo, R2 is hydrogen; R 3 is selected from phenyl, pyridinyl, furyl, or thienyl, optionally substituted with up to two substituents chosen independently among: a) C 1 3 alkyl or C 3 cycloalkyl, b) C 1 I 3 fluoroalkyl or C 3 flu6rocycloalkyl, c) C 1 -6alkoxy or C 3 -6cycloalkyloxy, d) C 1 3 flUoroalkoxy or C 3 fluorocycloalkoxy, e) C 13 alkylthio or C 3 cycloalkylthio, f) halo, -110- 20066 *14 g) -OH, h) -NO 2 Si) j) -NHCONR 9 R 0 k) -X 2 -y 2 -Ar 3 wherein, X 2 is 1) -CH 2 or 2) a bond; Y2 is 1) -0- 2) or 3) a bond; Ar 3 is phenyl, pyridinyl, or pyrimidinyl optionally substituted with up to two substituents chosen independently among: 1) CI- 3 alkyl or C 3 cycloalkyl, optionally substituted with -OH, or 2) -CCH 2 CO 2 H, R 4 and R 5 are independently selected from: a) hydrogen, b) Ci. 3 alkyl or C 3 cycloalkyl, R and R 7 are independently chosen from among: a) hydrogen, b) C-4alkyl or C 3 4 cycloalkyl, R 8 R" 1 and R 1 2 are chosen from among: a) hydrogen, or b) Ci-5 or C 3 -5 cycloalkyl; and R 9 and R' 1 are independently chosen from among: a) hydrogen, or b) C 1 -4alkyl or C 3 -4cycloalkyl. -111- 6. A compound according to claim 1, selected from the group consisting of CH, CH 3 F- 0 SHO3C SS HO S CH I/ N\ 2~ H 3 C NH 2 H 2 C -N N4 C' N S S H,,S CH, 7 0 -J 0 HOH CH,- NH C 2 HO S CHCH C1 2 Hz N S N, HO NO S ii I 3 H-C 0 W1 -12 NT cm, IH C N HO m OH OCH, HZC 0 OH 0- CH3 C02", 113 £UUOO a CH, 4 HO H 3 N N CH, s CH, CH 2 C-IH HO, 3 2 C NH N CH, M 3 C Hz 2 CH, sk*-O
  3. 114-
  4. 20066- J *-J X~C~N CH H~C CH C-CH-I cf H~C /CHN H-I H~C ~a 115 .;.Jvuu ''2 CH, N-OH /,IN H~C \A CH 3 HaC-/ N ca\\Ir--o 116 CH 3 HC CH3 H3C N S H3CN 0 1 1 OH ICHZ NN= S r 2CH CH 3 H 2 C N 0, CH3 Coal, 117- :2 CH2 H, C ~N H3H I ClH CH3 HaC/ I CHZ 00 118 -VUUU o-C.Uj CH, H 2C-4/ s S "CH2 H 2 C HN N, K_ F 119 4 I 0 ,c NH 2 POO Sao 120 -'JUuu H3cH H 3 C HN -I~ CH CH, H= N N s Ho Ho CH, C- CH, H C 'cH 3 CH C H 2 N' pot", skes, 121 AAUVV C H:C QF HO S CH Y N s FHf CO OH 122 CH., 0 N-C N' S, N.~ H:C 0 0 CH, G H3 H 3 C jN H2,C-O C H 3 C CH3 CH 3 HC ~N H3C Icx 123 01AD", A..UU CH .1CH.3 CH2 s HO s 71 CH3 onrc;:, 0 H~C HN 124 HCC H N HO N~I s 0 0*CH HC- N SN C_ 0H 125 OH 3 H 3 C x -I S S. H 3 C 0 F CH3 F Q SIO 126 127 7. A pharmaceutical composition comprising a non-toxic therapeutically effective amount of a compound according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier. 8. A method of preparing an aryl thiopene derivative which is useful as a phosphodiesterase (PDE) IV inhibitor, which method is substantially as hereinbefore described with reference to the Methods of Synthesis Examples. 9. An anti-asthma pharmaceutical formulation comprising an acceptable, non-toxic, therapeutically effective amount of a compound of formula as defined in any one of claims 1 to 6 in association with a pharmaceutically acceptable carrier. 10. A pharmaceutical composition for treating a phosphodiesterase (PDE) IV mediated disease by inhibiting phosphodiesterase (PDE) IV, the composition comprising a non-toxic therapeutically effective amount of a compound according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier. 11. A method of treating asthma, the method comprising administration to a 15 patient of a non-toxic therapeutically effective amount of a compound according to any one of claims 1 to 6, or of a formulation according to claim 9. 12. A method of treating asthma, the method comprising administration to a patient of a non-toxic therapeutically effective amount of a compound according to claim 1, or of a pharmaceutical composition according to claim 7. 20 13. A compound according to any one of claims 1 to 6 or a pharmaceutical composition according to claim 7 or claim 9 when used for treating asthma in a patient. 14. Use of a compound according to any one of claims 1 to 6 in the manufacture of a medicament for treating asthma in a patient. A method of treating a phosphodiesterase (PDE) IV mediated disease by inhibiting phosphodiesterase (PDE) IV, the method comprising administration to a patient of a non-toxic therapeutically effective amount of a compound according to any one of claims 1 to 6 or of a pharmaceutical composition according to claim 7 or claim 16. The method according to claim 15 comprising administration to a patient of a non-toxic therapeutically effective amount of a compound according to claim 1. 17. A compound according to any one of claims 1 to 6 or a pharmaceutical composition according to claim 7 or claim 10 when used for treating phosphodiesterase (PDE) IV mediated disease by inhibiting phosphodiesterase (PDE) IV in a patient -1 [R:\LIBAA]08614.doc:ACR [R:\LIBAA]08614.doc:ACR 128 18. Use of a compound according to any one of claims 1 to 6 in the manufacture of a medicament for treating phosphodiesterase (PDE) IV mediated disease by inhibiting phosphodiesterase (PDE) IV in a patient 19. A phosphodiesterase (PDE) IV inhibitor pharmaceutical composition comprising an acceptable phosphodiesterase (PDE) IV inhibiting amount, effective to increase the cellular level of cAMP, of a compound of formula as defined in any one of claims 1 to 6 in association with a pharmaceutically acceptable carrier. Use of a compound of formula as defined in any one of claims 1 to 6 as a phosphodiesterase (PDE) IV inhibitor. 21. A method for treating a phosphodiesterase (PDE) IV mediated disease by increasing the cellular level of cAMP, the method comprising administration to a patient of a non-toxic therapeutically effective amount of a compound according to any one of claims 1 to 6 or of a pharmaceutical composition according to claim 7 or claim 19. 22. A compound according to any one of claims 1 to 6 or a pharmaceutical 15 composition according to claim 7 or claim 19 when used for treating a phosphodiesterase (PDE) IV mediated disease by increasing the cellular level of cAMP. 23. Use of a compound according to any one of claims 1 to 6 in the manufacture of a medicament for treating a phosphodiesterase (PDE) IV mediated disease by increasing the cellular level of cAMP. 20 Dated 19 February, 2001 Merck Co., Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON [R:\LIBAA]08614.doc:ACR
AU93347/98A 1997-10-03 1998-10-01 Aryl thiophene derivatives as PDE IV inhibitors Ceased AU732406B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6091497P 1997-10-03 1997-10-03
US60/060914 1997-10-03
GB9808109 1998-04-16
GBGB9808109.4A GB9808109D0 (en) 1998-04-16 1998-04-16 Aryl thiophene derivatives as pde iv inhibitors
PCT/CA1998/000931 WO1999018099A1 (en) 1997-10-03 1998-10-01 Aryl thiophene derivatives as pde iv inhibitors

Publications (2)

Publication Number Publication Date
AU9334798A AU9334798A (en) 1999-04-27
AU732406B2 true AU732406B2 (en) 2001-04-26

Family

ID=26313480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU93347/98A Ceased AU732406B2 (en) 1997-10-03 1998-10-01 Aryl thiophene derivatives as PDE IV inhibitors

Country Status (5)

Country Link
EP (1) EP1019399A1 (en)
JP (1) JP3409029B2 (en)
AU (1) AU732406B2 (en)
CA (1) CA2305414A1 (en)
WO (1) WO1999018099A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002226464A (en) * 2001-01-30 2002-08-14 Sumitomo Pharmaceut Co Ltd Triaryl analogue and its use
JP2004535381A (en) * 2001-04-13 2004-11-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド Inhibitors of c-Jun N-terminal kinase (JNK) and other protein kinases
WO2003027100A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
JP4331951B2 (en) * 2002-08-30 2009-09-16 富士フイルム株式会社 Novel compound and optical element using the same
MX2007002178A (en) 2004-08-23 2007-04-02 Wyeth Corp Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases.
CN101429189B (en) * 2008-12-24 2014-07-23 沈阳药科大学 2,3-disubstituted aryl thiophene derivants and uses thereof
CN104906100A (en) * 2009-05-26 2015-09-16 艾伯维巴哈马有限公司 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103391766B (en) * 2011-02-07 2018-05-25 塞法姆公司 For treating the new composition of cystic fibrosis
EP2994463B1 (en) 2013-05-07 2017-10-25 Galapagos NV Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX2016001602A (en) 2013-08-08 2016-12-15 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3531497A (en) * 1967-02-21 1970-09-29 Upjohn Co 2,4,5 - triphenyl - (and substituted triphenyl) - 3 - acetonitriles of pyrrole
GB1271082A (en) * 1968-05-07 1972-04-19 Wyeth John & Brother Ltd Furan, pyrrole and thiophene derivatives
GB1381860A (en) * 1971-06-03 1975-01-29 Wyeth John & Brother Ltd Tetrazole derivatives
DE3873278T2 (en) * 1987-09-22 1993-02-25 Merck & Co Inc ARYL-SUBSTITUTED THIOPHEN-3-OLE, THEIR DERIVATIVES AND ANALOGS AS LIPOXYGENASE INHIBITORS.
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
JPH06135961A (en) * 1992-10-23 1994-05-17 Nippon Iyakuhin Kogyo Kk New diphynelpyrrolylfuran derivative
FR2730996B1 (en) * 1995-02-23 1997-06-20 Adir NOVEL THIOPHENE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JPH11228535A (en) * 1995-05-30 1999-08-24 Tsumura & Co New compound and anti-dermatitis agent
PT853083E (en) * 1997-01-06 2001-12-28 Pfizer COMPOSITION OF PYRIDILFURANE AND PYRIDYLTHOPHENE AND ITS PHARMACEUTICAL UTILIZATION

Also Published As

Publication number Publication date
WO1999018099B1 (en) 1999-05-27
EP1019399A1 (en) 2000-07-19
CA2305414A1 (en) 1999-04-15
AU9334798A (en) 1999-04-27
WO1999018099A1 (en) 1999-04-15
JP2001519347A (en) 2001-10-23
JP3409029B2 (en) 2003-05-19

Similar Documents

Publication Publication Date Title
US6034089A (en) Aryl thiophene derivatives as PDE IV inhibitors
AU732177B2 (en) Aryl furan derivatives as PDE IV inhibitors
US5710170A (en) Tri-aryl ethane derivatives as PDE IV inhibitors
JP3856465B2 (en) Trisubstituted phenyl derivatives useful as PDE IV inhibitors
USRE47142E1 (en) Compounds and methods for treating inflammatory and fibrotic disorders
KR102066336B1 (en) 4-hydroxy-3- (heteroaryl) pyridin-2-one APJ agonist for use in the treatment of cardiovascular disorders
JP3581714B2 (en) Styryl derivatives and methods for their production
AU677294B2 (en) Styryl derivatives, their preparation and use as PDE-IV inhibitors
AU732406B2 (en) Aryl thiophene derivatives as PDE IV inhibitors
US20080318958A1 (en) New utilities of tricyclic compounds
WO2020151566A1 (en) Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
JPH08505158A (en) Trisubstituted phenyl derivatives as phosphodiesterase inhibitors and process for their preparation
WO1997022585A1 (en) Diphenyl pyridyl ethane derivatives as pde iv inhibitors
CA2238875C (en) Tri-aryl ethane derivatives as pde iv inhibitors
JPH10503174A (en) Tri-substituted phenyl derivatives useful as PDE IV inhibitors
JPH10504530A (en) Tri-substituted phenyl derivatives useful as PDE IV inhibitors
AU2789100A (en) Pde iv inhibiting compounds, compositions and methods of treatment
US6200993B1 (en) Heterosubstituted pyridine derivatives as PDE4 inhibitors
WO2000064874A2 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
WO2021170658A1 (en) Heterocyclic compounds for modulating nr2f6
KR100501865B1 (en) Tri-Substituted Phenyl Derivatives Useful as PDE IV Inhibitors
EP0873310A1 (en) Diphenyl pyridyl ethane derivatives as pde iv inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired